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to demonstrate any association with NRT use. Our con-
clusions agree with recent statements from authoritative 
bodies.
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Abbreviations
ADHD  Attention-deficit/hyperactivity disorder
AMI  Acute myocardial infarction
CAF  Critical assessment form
CI  Confidence interval
CVD  Cardiovascular disease
ENDS  Electronic nicotine delivery systems
FDA  Food and Drug Administration
GI  Gastrointestinal
HR  Hazard ratio
NICE  National Institute for Health and Care Excellence
NRT  Nicotine replacement therapy
OR  Odds ratio
RCT  Randomized clinical trial
RR  Relative risk
SAHE  Serious adverse health effect
Introduction
The active ingredient in pharmaceutical nicotine replace-
ment therapy (NRT) products is nicotine. Millions of peo-
ple are exposed daily to nicotine by using these smoking 
cessation products (Royal College of Physicians 2016; 
Siahpush et al. 2015). In this review, pharmaceutical NRTs 
are products regulated as drugs or medicines to aid smok-
ing cessation (Royal College of Physicians 2016; US Food 
Abstract We conducted a systematic literature review to 
identify and critically evaluate studies of serious adverse 
health effects (SAHEs) in humans using nicotine replace-
ment therapy (NRT) products. Serious adverse health 
effects refer to adverse events, leading to substantial dis-
ruption of the ability to conduct normal life functions. 
Strength of evidence evaluations and conclusions were also 
determined for the identified SAHEs. We evaluated 34 epi-
demiological studies and clinical trials, relating NRT use 
to cancer, reproduction/development, CVD, stroke and/or 
other SAHEs in patients, and four meta-analyses on effects 
in healthy populations. The overall evidence suffers from 
many limitations, the most significant being the short-term 
exposure (≤12 weeks) and follow-up to NRT product use 
in most of the studies, the common failure to account for 
changes in smoking behaviour following NRT use, and 
the sparse information on SAHEs by type of NRT prod-
uct used. The only SAHE from NRT exposure we identi-
fied was an increase in respiratory congenital abnormalities 
reported in one study. Limited evidence indicated a lack of 
effect between NRT exposure and SAHEs for CVD and 
various reproduction/developmental endpoints. For can-
cer, stroke and other SAHEs, the evidence was inadequate 
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and Drug Administration 2013). Pharmaceutical NRT 
products have been available, for over three decades, with 
current forms such as chewing gum, lozenge, oral tablet, 
skin patch, nasal spray and inhaler (Ferguson et al. 2011; 
Royal College of Physicians 2016). Because daily expo-
sure to these products depends on individual preferences 
and needs, a broad range of maximum plasma nicotine lev-
els from 6 to 43 ng/ml has been reported (Haussmann and 
Fariss 2016; Schneider et al. 2001; Shiffman et al. 2005). 
In the USA, the recommended duration of use for NRT 
products is 8–12 weeks depending on the product form (US 
Food and Drug Administration 2013). However, the US 
Food and Drug Administration (FDA) recently proposed 
the possibility of a 6-month extension of NRT use limits 
with healthcare provider consultation (Fucito et al. 2014; 
US Food and Drug Administration 2013). It seems that 
uncertainty regarding the potential adverse health effects 
of long-term use of NRT products (such as cancer) may 
be, in part, responsible for the proposed increase in dura-
tion of use (from 3 to 6 months) being relatively modest 
(Shields 2011; US Surgeon General 2014). In other coun-
tries, including the UK, the medicines regulatory authori-
ties appear to have a more relaxed approach to the long-
term use of pharmaceutical NRT products. For example, 
since 2010, UK smokers have been encouraged to continue 
NRT use if needed to maintain smoking cessation. In other 
words, the consumer should decide how long to continue 
using NRT products (Kostygina et al. 2016; McNeill et al. 
2001; Royal College of Physicians 2016).
Nicotine per se is a unique active ingredient for a con-
sumer product in that the majority of nicotine’s effects are 
mediated by binding and activating nicotinic acetylcholine 
(nACh) receptors in a wide variety of neuronal (central and 
peripheral nervous system) and non-neuronal tissue. Con-
sequently, nicotine exposure affects numerous systems, 
including neurological, neuromuscular, cardiovascular, res-
piratory, immunological and gastrointestinal. The presence 
of different types of nACh receptors, receptor up-regula-
tion and receptor desensitization influences these complex 
physiological effects (Lam et al. 2016; Marks et al. 1987; 
Renda and Nashmi 2014). Evidence from experimental 
animal models clearly demonstrate nicotine’s ability to 
enhance existing tissue injury and diseases such as cancer, 
cardiovascular disease, stroke, pancreatitis, peptic ulcer, 
renal injury and developmental (e.g. pulmonary, repro-
ductive and central nervous system) abnormalities (Arany 
et al. 2011; Bruin et al. 2010; Chowdhury et al. 1995; Hall 
et al. 2016; Haussmann and Fariss 2016; Lau et al. 2006; 
Qiu et al. 1991; Rehan et al. 2012; Wang et al. 1997). 
These reported adverse health effects were observed fol-
lowing short-term exposure to nicotine per se (<12 weeks) 
and appear to be dependent on nicotine activation of nACh 
receptors in the affected tissue.
In regard to potential serious adverse health effects 
(SAHEs) associated with long-term use of pharmaceutical 
NRT products in humans, the United Kingdom’s National 
Institute for Health and Care Excellence (NICE) concluded 
that “evidence is available from studies with up to 5-year 
follow-up which suggests that ‘pure’ nicotine, in the form 
available in NRT products, does not pose a significant 
health risk” (National Institute for Health and Care Excel-
lence 2013). In addition, a recent Surgeon General’s report 
concluded that inadequate evidence is available “to infer 
the presence or absence of a causal relationship between 
exposure to nicotine and risk of cancer” (US Surgeon Gen-
eral 2014). In contrast to these authoritative statements, 
FDA classifies NRT therapies as a Pregnancy Category 
“C” or “D” developmental hazard. Category D classifica-
tion indicates “studies, adequate well-controlled or obser-
vational, in pregnant women have demonstrated a risk to 
the fetus” (Meadows 2001). Furthermore, potential SAHEs 
with pharmaceutical NRT product use are suggested based 
on government warning statements for such products. 
These include warnings against potential major adverse 
effects in the cardiovascular system (heart disease), gastro-
intestinal system (stomach ulcers) and diabetes with NRT 
product use (US Food and Drug Administration 2015a). 
Unfortunately, a systematic review of the scientific evi-
dence related to potential SAHEs of pharmaceutical NRT 
products is not available.
The work described here has two main objectives: to 
identify and critically evaluate relevant studies pertaining 
to SAHEs in humans, if any, of pharmaceutical NRT and 
to provide strength of evidence evaluation and conclusions 
for these effects. For this review, we did not consider evi-
dence relating SAHEs from exposure to snus (or any other 
smokeless tobacco product) or electronic nicotine delivery 
systems (ENDS). Currently, these commercial products 
are regulated as tobacco products and are not developed, 
approved and licensed as drugs or medicines to aid smok-
ing cessation (Royal College of Physicians 2016; US Food 
and Drug Administration 2016). The potential adverse 
health effects of snus have been well studied (Lee 2011, 
2013), and ENDS are relatively new products with tre-
mendous diversity in product design and aerosol delivery. 
Finally, the words pharmaceutical NRT and NRT are used 
synonymously in this review.
Methods
Inclusion/exclusion criteria
Attention was restricted to epidemiological studies and 
clinical trials of NRT describing results relating to SAHEs. 
For this review, SAHEs are defined as adverse events 
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leading to substantial disruption of the ability to conduct 
normal life functions, including those that lead to hospitali-
zation, significant disability or birth defects, are life-threat-
ening or result in death or require medical intervention 
to prevent one of the above outcomes (Little and Ebbert 
2015; US Food and Drug Administration 2013). These do 
not include acute side effects such as nausea, vomiting and 
altered heart rate. Relevant reviews were also sought, partly 
to look for relevant publications, and partly for citation in 
this report. No attempt was made to identify individual 
clinical trials of smoking cessation in healthy individuals, 
since use of NRT is usually short term and serious adverse 
events are rare. Rather, we sought published meta-analyses 
of such trials, although also considering meta-analyses 
which included a small proportion of studies in diseased 
subjects.
Clinical and epidemiological studies in which phar-
maceutical NRT products were used are included. In this 
review, pharmaceutical NRTs are products regulated as 
drugs or medicines to aid smoking cessation (Royal Col-
lege of Physicians 2016; US Food and Drug Administra-
tion 2013). Studies that use any product that contains 
tobacco are excluded as they are regulated as tobacco 
products. Epidemiological studies on Swedish snus (a 
smokeless tobacco) are often used as an indirect measure 
of the potential adverse health effects of long-term nico-
tine use in humans (Benowitz 2011). However, for this 
review, exposure to NRT products and snus (or any other 
smokeless tobacco product) is not considered equivalent. 
NRT products are approved or licensed (regulated) as 
drugs or medicines to aid in smoking cessation, whereas 
snus and other smokeless tobacco products are regulated 
as tobacco products (Royal College of Physicians 2016; 
US Food and Drug Administration 2016). Likewise, stud-
ies that use ENDS products are excluded as they are cur-
rently undergoing regulatory consideration as tobacco 
products, not as drugs or medicines for aiding smoking 
cessation (Royal College of Physicians 2016; US Food and 
Drug Administration 2016).
Relevant publications were subdivided by type of study 
(epidemiological, clinical trials) and outcome [cancer, 
reproductive/developmental, cardiovascular disease (CVD), 
stroke, other SAHEs seen in patients, and other SAHEs 
seen in healthy populations].
Literature searches
The first step was a PubMed search on 24 July 2015, using 
the terms:
(“NRT”[All Fields] OR “nicotine replacement 
therapy”[All Fields] OR “Nicotine chewing gum”[All 
Fields] OR “Nicotine patch”[All Fields] OR “Tobacco 
use cessation”[All Fields] OR “Tobacco use Cessation/
methods”[All Fields]) AND (“Kidney disease”[All Fields] 
OR “Diabetes”[All Fields] OR “GI tract”[All Fields] 
OR “Stomach”[All fields] OR “Pancreas”[All Fields] 
OR “Pancreatic”[All Fields] OR “Reproductive”[All 
Fields] OR “Reproduction”[All Fields] OR “Preg-
nancy Complications”[Mesh terms] OR “Pregnancy 
Outcome”[Mesh terms] OR “Birth weight”[Mesh 
terms] OR “Infant, low birth weight”[Mesh terms] 
OR “Infant, newborn, diseases”[Mesh terms] OR 
“child development”[Mesh terms] OR “Cardiovascu-
lar disease”[All Fields] OR “Stroke”[All Fields] OR 
“Cancer”[All Fields]) AND ((“1960/01/01”[PDAT]: 
“3000/12/31”[PDAT]) AND “humans”[MeSH Terms]).
Abstracts of papers and reviews identified were 
inspected, with reasons for rejection noted for those clearly 
irrelevant, and publications of potential interest obtained. 
Papers read were either accepted or rejected with reasons 
noted (Table 1).
Relevant clinical trial reviews in the Cochrane library 
were also obtained. Reference lists of accepted papers and 
reviews were then examined and further papers obtained 
and read, with additional papers accepted and reasons for 
rejection noted for others (Table 1).
Near finalization of the paper an additional PubMed 
search was conducted on 30 November 2015 using the 
same search terms described above.
Assessment of studies
For each topic, a critical assessment form (CAF) was com-
pleted for each publication. Notes for completing CAFs are 
given in Supplementary File 1, together with the completed 
CAFs. Each form provides a detailed summary of study 
design, findings and strengths and weaknesses.
There are two types of CAF. The first, for publications 
describing results of individual studies, is divided into 18 
sections: form no.; topic; author(s); title; source; study 
type; study location; population studied and inclusion cri-
teria; nicotine exposures; treatment groups and sizes; rele-
vant endpoints; confounding variables; other relevant study 
details; relevant findings; authors’ main relevant conclu-
sions; strengths and weaknesses mentioned; study quality 
score (for epidemiology studies) or risk of bias (for clinical 
trials); and comments.
The second, for publications describing results of meta-
analyses of SAHEs in clinical trials of healthy people, is 
divided into 17 sections: form no.; topic; author(s); title; 
source; meta-analysis type; location of studies; populations 
studied and inclusion criteria; searches; nicotine exposures; 
numbers of subjects considered; relevant endpoints; rel-
evant findings; authors’ main relevant conclusions; study 
quality assessment; strengths and weaknesses mentioned; 
and comments.
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Table 1  Literature searches and reasons for rejection
a Note that only one reason for rejection was applied to an abstract or paper, although, particularly for the abstracts, more than one reason may 
have applied
b The 25 papers rejected were Anthonisen et al. (2005), Benowitz and Gourlay (1997), Cordier (2014), Dempsey and Benowitz (2001), Ebbert 
et al. (2007), Ford and Zlabek (2005), Forest (2010), Harrell et al. (2014), Hughes (2000), Jacobson and Jaklitsch (2013), Joseph and Fu (2003), 
Kotz et al. (2015), Lancaster (2014), Lavelle et al. (2003), Marsh et al. (2005), Myung et al. (2007), Nicholson et al. (2010), Osadchy et al. 
(2009), Pauly and Slotkin (2008), Reuther and Brennan (2014), Shahab and Goniewicz (2014), Smith et al. (2002), Steinberg et al. (2009), Wein-
berger et al. (2014), Zaton´ski and Zaton´ski (2015)
c The 7 papers rejected were Aubin et al. (2008), Eliasson et al. (1996), Haustein et al. (2002), Oncken et al. (1996, 1997), Shiffman et al. 
(2002), Tappin et al. (2015)
d The 2 papers rejected were Black et al. (2014) and Adams et al. (2013)
Step Result N Reasons for rejectiona/papers completed
PubMed search on 24 July 2015 811 hits
 Abstracts examined 757 rejected 36 NRT not abbreviation for nicotine replacement therapy
9 Study of e-cigarettes
187 Not a study of nicotine replacement therapy
10 In vitro or animal study
185 Study of smoking cessation (or cutting down) with no relevant endpoints
95 Endpoints not considered serious health effects
190 Review or commentary not providing relevant data
45 Other reasons (including case reports)
 Papers examined 25 rejectedb 8 No relevant endpoints
13 Review with no new data or citations
3 Case reports
1 No appropriate comparison groups
 Papers examined 29 accepted 23 Papers: Berlin et al. (2014), Carandang et al. (2011), Coleman et al. (2012b), 
Cooper et al. (2014a), Dhalwani et al. (2015), El-Mohandes et al. (2013), Elzi 
et al. (2006), Gaither et al. (2009), Greenland et al. (1998), Hubbard et al. 
(2005), Lassen et al. (2010), Lee et al. (2013), Murray et al. (2009), Oncken 
et al. (2008), Panos et al. (2010), Pollak et al. (2007), Schroeder et al. (2002), 
Strandberg-Larsen et al. (2008), Swamy et al. (2009), Tappin et al. (2015), 
Thomsen et al. (2010), Torp-Pedersen et al. (2010), Zhu et al. (2014)
6 Reviews: Bruin et al. (2010), Coleman et al. (2011, 2012a), Forinash et al. 
(2010), Mills et al. (2014), Rore et al. (2008)
Cochrane reviews 1 accepted Stead et al. (2012)
Secondary references 22 found
 Papers examined 7 rejectedc 5 No relevant endpoints
1 Review with no new data or citations
1 Effects of smoking and nicotine replacement therapy indistinguishable
 Papers examined 15 accepted Cooper et al. (2014b), Joseph et al. (1996), Kapur et al. (2001), Kimmel et al. 
(2001), Meine et al. (2005), Milidou et al. (2012), Mills et al. (2010), Mohi-
uddin et al. (2007), Moore et al. (2009), Morales-Suarez-Varela et al. (2006), 
Paciullo et al. (2009), Rennard et al. (1994), Tzivoni et al. (1998), Wisborg 
et al. (2000) and Woolf et al. (2012)
PubMed search on 30 November 2015 46 hits
 Abstracts examined 44 rejected 13 Paper previously considered
3 NRT not abbreviation for nicotine replacement therapy
1 Study of e-cigarettes
1 In vitro or animal study
15 Study of smoking cessation (or cutting down) with no relevant endpoints
4 Endpoints not considered serious health effects
5 Review or commentary not providing relevant data
2 Other reasons (including case reports)
 Papers examined 2 rejectedd 1 Commentary on paper we had with no new data
1 Study of Medicaid not NRT
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The CAFs are presented in Supplementary File 1 sepa-
rately by topic (e.g. cancer and reproduction/development) 
and are numbered consecutively. Exceptionally, where one 
publication provides results for multiple topics, the CAFs 
use versions labelled, e.g. 28A, 28B and 28C.
Study quality was assessed as good, fair or poor based 
on the NIH published quality assessment tools for obser-
vational cohort and cross-sectional studies (National 
Heart Lung and Blood Institute 2014b) and case–con-
trol studies (National Heart Lung and Blood Institute 
2014a). For clinical trials, risk of bias was assessed using 
the Cochrane Collaboration’s tool (Higgins et al. 2011). 
Supplementary File 2 summarizes methods used for 
both assessment types and gives detailed results for each 
study. Supplementary Files 3, 4 and 5 give the results 
from the assessments for, respectively, reproduction/
development, CVD and other SAHEs in patients. Supple-
mentary File 6 gives assessments for the meta-analyses 
of other SAHEs.
Summarizing results for an endpoint
The method varies with the extent of available data and 
includes a simple textual description, a table of results and/
or a meta-analysis. Conducting a meta-analysis requires 
at least three studies reporting relevant results for the 
endpoint, but also on the results being reported similarly 
enough to allow combination over studies.
Results presented are always given with the NRT 
exposed group as the test group and the non-exposed as the 
comparison group. Thus, estimates of the RR, odds ratio 
(OR) or hazard ratio (HR) always relate to the NRT/non-
NRT ratio, and mean differences are always NRT minus 
non-NRT. Generally, the analysis is restricted to those who 
have smoked, though exceptions where the source paper 
does not allow this are indicated as appropriate. Often, the 
NRT versus non-NRT comparison statistic has to be esti-
mated from the source publication using standard methods. 
Examples where this is necessary include estimating the 
unadjusted RR and its 95 % confidence interval (CI) in a 
clinical trial where numbers affected and at risk are availa-
ble for the NRT and placebo groups; estimating unadjusted 
mean differences and 95 % CIs from group-specific means 
and standard deviations; estimating CIs from means and p 
values; and estimating RRs, ORs or HRs and their 95 % 
CIs for a more relevant comparison than that reported (e.g. 
relative to never smokers).
Strength of evidence assessment
This was carried out for each endpoint, and overall for 
the topic. The criteria for evaluating specific SAHEs 
were adapted and modified from those outlined by the 
International Agency for Research on Cancer (IARC) 
(International Agency for Research on Cancer 2007). 
A major modification to the IARC strength of evidence 
assessment is the separation of their classification “evi-
dence suggesting lack of carcinogenicity” into “limited evi-
dence suggesting a lack of effect” and “sufficient evidence 
of a lack of effect”. With this revised classification in place, 
the strength of evidence conclusions can be neutral (inad-
equate evidence) or can be deemed limited or sufficient in 
both directions, for an adverse effect or a lack of an adverse 
effect (Haussmann and Fariss 2016). The criteria used were 
as follows.
Sufficient evidence: A causal relationship has been estab-
lished in humans between exposure to NRT and this SAHE 
in humans. A positive association was observed in which 
chance, bias and confounding factors could be ruled out 
with reasonable confidence. Conclusive studies have been 
conducted.
Limited evidence: A positive association was observed 
between exposure to NRT and this SAHE, but chance, bias 
and confounding factors could not all be ruled out with rea-
sonable confidence. Conclusive studies are lacking.
Inadequate evidence: The available studies are of insuf-
ficient quality, consistency or statistical power to permit a 
conclusion regarding a positive association between expo-
sure to NRT and this SAHE. This category includes no data 
or conflicting evidence in multiple studies.
Limited evidence suggesting a lack of effect: A statisti-
cally significant association was not observed between 
exposure to NRT and this SAHE, but a true relationship 
could not be ruled out with reasonable confidence because 
of a lack of statistical power, bias and/or confounding.
Sufficient evidence of a lack of effect: A lack of associa-
tion has been observed between exposure to NRT and this 
SAHE, based on studies of adequate quality, consistency 
and statistical power. The possibility of a very small risk at 
relevant exposure levels can never be excluded.
Results
Literature searches
Table 1 summarizes results of the original searches. Forty-
four relevant publications were found, six being reviews 
used only for searching for secondary references. Of the 
rest, one related to cancer, 19 to reproduction/develop-
ment, 10 to CVD, three to stroke, five to other SAHEs on 
patients, and four were meta-analyses providing results 
for other SAHEs seen in healthy populations, some publi-
cations providing results for more than one endpoint. The 
additional PubMed search cited 33 more references, but 
none relevant to this review.
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Assessment of studies
Supplementary File 1 gives the completed CAFs, and Sup-
plementary File 2 study-specific information on study 
quality and risk of bias. Of the 12 epidemiological studies 
described, two were classified as of “good” quality, eight 
as “fair” and two as “poor”. Of the 14 clinical trials, eight 
were considered to have a “low” risk of bias, five a “high” 
risk, with one classified as “unclear”.
While details of the studies are described by topic below, 
it should be noted that the follow-up period was generally 
very short. The longest was the 7½-year follow-up for 
cancer of participants in the Lung Health Study (Murray 
et al. 2009) and the follow-up until 2011 for investigating 
attention-deficit/hyperactivity disorder (ADHD) of children 
born between 1996 and 2003 in the Danish National Birth 
Cohort study (Zhu et al. 2014). A follow-up until 2006 for 
investigating strabismus in the same study (Torp-Pedersen 
et al. 2010) and two-year follow-ups in two clinical trials 
(Cooper et al. 2014b; Mohiuddin et al. 2007) were the only 
other studies appearing to involve more than one year of 
follow-up.
Type of NRT
Of the 12 epidemiological studies, five (Carandang et al. 
2011; Kimmel et al. 2001; Meine et al. 2005; Paciullo et al. 
2009; Panos et al. 2010) only considered nicotine patches, 
while one (Murray et al. 2009) only considered nicotine 
gum. The remainder considered multiple, or any type of 
NRT, though results by type of NRT (gum, patch, inhaler) 
were only reported in two publications from the Danish 
Birth Cohort (birthweight—Lassen et al. (2010) and still-
birth rate in Strandberg-Larsen et al. (2008)) and in the UK 
case series analysis (acute myocardial infarction [AMI], 
stroke and death—(Hubbard et al. 2005)).
Of the 14 clinical trials, three trials (Pollak et al. 2007; 
Swamy et al. 2009; Thomsen et al. 2010) allowed the 
subjects allocated NRT to choose the type they preferred, 
one (Mohiuddin et al. 2007) did not define the type and 
one (Oncken et al. 2008) allocated subjects to gum. The 
remainder allocated subjects to nicotine patches. Results 
by type of NRT product were never reported in any clinical 
trial.
Of the four meta-analyses considered, one (Greenland 
et al. 1998) only concerned patches, the others considering 
results from multiple studies, each involving allocation to 
one or more NRT types. The limited evidence on risk of 
SAHEs by NRT type reported in these meta-analyses and 
in the epidemiological studies is considered in the follow-
ing sections.
Cancer
Based on findings from animal and mechanistic studies, a 
case for biological plausibility has been proposed for a poten-
tial role of nicotine in carcinogenesis (Cardinale et al. 2012; 
Grando 2014; Haussmann and Fariss 2016; Improgo et al. 
2011). Carcinogenesis is a multistage process that involves 
three stages: initiation, promotion and progression (Klaunig 
2013). For initiation, a substance must exhibit genotoxic 
properties which have been reported for nicotine at concen-
trations relevant to NRT use (Haussmann and Fariss 2016). 
Similarly, nicotine has been reported to stimulate cell pro-
liferation, inhibit apoptosis, induce angiogenesis and inhibit 
immune function (Cardinale et al. 2012; Grando 2014). 
Thus, there is considerable evidence that nicotine exposure 
(at levels relevant to NRT users) can affect many of the cel-
lular processes that are considered important for the initia-
tion, promotion or progression of the carcinogenic process. In 
fact, a recent comprehensive review concludes that a major-
ity of studies provides sufficient evidence for an association 
between short-term nicotine exposure and enhanced car-
cinogenesis of cancer cells inoculated in mice (Haussmann 
and Fariss 2016). The results from these non-clinical stud-
ies clearly support investigating similar nicotine effects with 
NRT use, especially in smokers or former smokers where ini-
tiated cancer cells may be present.
For NRT users, only one useful publication was found 
(Murray et al. 2009)—see CAF 1. This described follow-up 
of participants in the Lung Health Study, an RCT of mid-
dle-aged volunteers with asymptomatic airways obstruction 
randomized to a smoking intervention involving encourage-
ment to use nicotine gum. The 7½-year follow-up started 
after the 5-year intervention period and compared cancer 
risk in 3315 participants alive and cancer-free at start of 
follow-up by NRT use in the preceding 5 years. The study 
quality was rated “good”.
After adjustment for baseline age, sex, cigarettes per day 
and lifetime pack-years smoking, NRT use was unrelated to 
lung cancer, gastrointestinal (GI) cancer or all cancer (see 
Table 2), regardless of adjustment for pack-years cigarette use 
in the 5 years following randomization. Nor were relation-
ships seen with NRT use when mean daily use was replaced 
by any NRT use (results not shown). In contrast, pack-years 
cigarette use was significantly related to lung cancer risk, 
whether or not adjusted for daily NRT use. The authors noted 
that the results add “credence to our conclusion that nicotine 
replacement therapy does not cause cancer”.
Much more limited evidence comes from a 12-month 
follow-up study of HIV-infected individuals (Elzi et al. 
(2006), CAF 24). This study reported one lung cancer death 
among 34 smokers participating in a smoking cessation 
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program where NRT was made available, and one among 
383 non-participating smokers, a comparison which is not 
statistically significant at p < 0.05, or adjusted for the par-
ticipants having higher baseline cigarette consumption and 
disease rates than non-participants.
Given the few publications, the limited follow-up for a 
chronic disease like cancer, and the difficulty of reliably 
disentangling effects of NRT and smoking, we consider 
there is inadequate evidence to permit a conclusion regard-
ing an association between exposure to NRT and cancer.
Reproduction/development
Based on findings from published animal studies, suffi-
cient evidence supports an association between short-term 
nicotine exposure and adverse reproductive and develop-
mental effects (Bruin et al. 2010; Hall et al. 2016; Rehan 
et al. 2012; Slotkin 2008; Spindel and McEvoy 2016; Wong 
et al. 2015). This is not surprising since nicotine binds and 
activates nAChRs, mimicking the effects of the endogenous 
ligand for this receptor, acetylcholine. It is well known that 
during the development of the central nervous system, neu-
rotransmitters such as acetylcholine play a critical role in 
brain assembly from early embryonic stages to early adult-
hood (Slotkin 2008). These nicotinic acetylcholine recep-
tors also play an important role in coordinating the develop-
ment of other organ systems including reproductive organs 
and the lung (Bruin et al. 2010; Rehan et al. 2012; Spindel 
and McEvoy 2016). As a result, animal studies have con-
sistently reported that prenatal exposure to nicotine can 
result in deficits in reproductive function (Bruin et al. 2010; 
Wong et al. 2015), behavioural and cognitive dysfunction 
such as hyperactivity, cognitive impairment, increased anx-
iety (Hall et al. 2016; Pauly and Slotkin 2008) as well as 
pulmonary effects such as impaired lung development and 
function (Rehan et al. 2012; Spindel and McEvoy 2016). 
For humans, there are conflicting views about the safe use 
of pharmaceutical NRT in pregnant women. Warnings from 
the US Food and Drug Administration place NRT thera-
pies in Pregnancy Categories “C” or “D” as developmental 
hazards (Slotkin 2008). In contrast, guidance from the UK 
Committee on Safety of Medicines encourages the use of 
pharmaceutical NRT products for smoking cessation dur-
ing pregnancy (Pauly and Slotkin 2008). Thus, the appar-
ent uncertainty in humans and the adverse effects clearly 
observed in animal studies supports the need for a compre-
hensive review of studies investigating reproductive/devel-
opmental effects in offspring of NRT users.
As summarized in Supplementary File 3, eight publica-
tions based on epidemiological studies provided informa-
tion on NRT and reproduction/development. Fuller study 
details are presented in CAFs 2 to 9. A cross-sectional 
study of women interviewed post-natally (Gaither et al. 
(2009), CAF 8, study quality “fair”) related NRT use in 
pregnancy to low birthweight and preterm birth of their 
offspring. Another study (Dhalwani et al. (2015), CAF 9, 
“fair”) used mother–child primary care records of children 
born in the UK to relate NRT prescription to incidence of 
major congenital abnormalities. The remainder (Lassen 
et al. (2010); Milidou et al. (2012); Morales-Suarez-Var-
ela et al. (2006); Strandberg-Larsen et al. (2008); Torp-
Pedersen et al. (2010); Zhu et al. (2014), CAFs 2 to 7, all 
“good”) derived from the Danish National Birth Cohort, 
each concerning different endpoints. The analyses all 
involve births in 1996 to 2003, though the publications 
vary in inclusion/exclusion criteria, and the comparison 
groups used for assessing NRT effects, some only reporting 
risks for women who used NRT and did not smoke. Com-
mon weaknesses of some of the analyses include the few 
relevant events in NRT users and the failure to control for 
changes in smoking behaviour after starting NRT.
Supplementary File 3 also summarizes 11 publica-
tions relating to eight clinical trials of smoking cessation 
(CAFs 10 to 20). Two (CAFs 13, 15) concern a multicentre 
Table 2  Results summary for NRT and cancer
a CAF critical assessment form. CAF 1 is a prospective study
b During the 7.5-year follow-up period following the 5-year period of the Lung Health Study
c Per piece of gum used per day on average during the Lung Health Study
d Baseline age, sex, cigarettes per day and lifetime pack-years of smoking
e Also adjusted for pack-years cigarette use over the 5-year period of the Lung Health Study
CAF no.a References Exposure Endpoint Casesb Hazard ratioc (95 % CI) Adjustments
1 Murray et al. (2009) Mean daily NRT use Lung cancer 75 1.02 (0.95–1.09) d
1.04 (0.97–1.12) e
GI cancer 33 0.97 (0.86–1.10) d
0.97 (0.82–1.14) e
All cancer 203 1.00 (0.96–1.05) d
1.01 (0.97–1.06) e
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trial in North Carolina (risk of bias “unclear”), one (Pol-
lak et al. 2007) reporting results for various endpoints, the 
other (Swamy et al. 2009) presenting a detailed analysis 
of adverse events following medical record review. Three 
(CAFs 16, 19 and 20) concern a multicentre trial in Eng-
land (risk of bias “low”), Coleman et al. (2012b) giving 
results for various endpoints recorded at or before birth, 
Cooper et al. (2014b) reporting on infant and maternal out-
comes at 2 years, and Cooper et al. (2014a) presenting an 
extremely detailed report, but providing no additional rel-
evant results. This is by far the largest study. Of the remain-
ing six studies, two provide little useful information, one 
(Kapur et al. (2001), CAF 11, risk of bias “low”) termi-
nated prematurely, the other (Schroeder et al. (2002), CAF 
12, risk of bias “high”) being small, with no controls. Of 
the other four studies, one (Oncken et al. (2008), CAF 14, 
risk of bias “low”) compared nicotine and placebo gum, 
two (Berlin et al. (2014) and Wisborg et al. (2000), CAFs 
10 and 18, both risk of bias “low”) compared nicotine and 
placebo patches, and one (El-Mohandes et al. (2013), CAF 
17, risk of bias “low”) compared cognitive behavioural 
therapy alone and in conjunction with nicotine patches. A 
similar comparison was made in the North Carolina study 
(Pollak et al. 2007; Swamy et al. 2009). The studies provide 
results for a various endpoints, considered in turn below.
Fetal loss and spontaneous abortion (Table 3): Each 
effect estimate is based on few exposed cases, none being 
significant (at p < 0.05). For stillbirth/fetal loss, the meta-
analysis estimate is 0.78 (95 % CI 0.45–1.33), with no 
heterogeneity. Stillbirth risk was also noted to be unaf-
fected by type of NRT in one study (Strandberg-Larsen 
et al. 2008).
Birthweight (Table 4): Eight studies provide relevant 
data, one clinical trial giving results in two publications 
(Pollak et al. 2007; Swamy et al. 2009). Seven studies pro-
vided heterogeneous (p = 0.01) estimates for risk of low 
birthweight, Oncken et al. (2008) reporting a highly signifi-
cant (p < 0.01) decreased risk of nicotine gum and the oth-
ers no significant differences. A random-effect meta-analy-
sis showed no overall effect, RR 0.81 (95 % CI 0.48–1.39). 
Five trials compared mean birthweight in NRT and placebo 
groups. Substantially higher birthweights associated with 
NRT exposure, by 200 g or more, were seen in three stud-
ies, significantly so (at p < 0.05) in two (Oncken et al. 2008; 
Wisborg et al. 2000), but not in the other (El-Mohandes 
et al. 2013). Smaller, non-significant, differences were seen 
in the other trials (Berlin et al. 2014; Pollak et al. 2007) 
and also in an epidemiological study (Lassen et al. 2010), 
which expressed the birthweight change per week of NRT 
use, and also found no significant variation by type of NRT. 
The inverse-variance weighted mean difference associated 
with NRT use was estimated as 142 (95 % CI −53 to 336) 
grams.
Gestational age (Table 5): Of five clinical trials 
reporting results for gestational age difference, two (El-
Mohandes et al. 2013; Oncken et al. 2008) reported a sig-
nificant increase associated with NRT allocation, the others 
no effect. The combined weighted estimate was 0.1 (95 % 
Table 3  Results summary for NRT and reproduction/development—fetal loss and spontaneous abortion
a CAF critical assessment form. CAF 3 is a prospective study, the others are clinical trials
b CBT cognitive behavioural therapy
c Exposed/unexposed cases
d HR hazard ratio, OR odds ratio, RR relative risk
e HR adjusted for maternal age, socio-occupational status and smoking. The HR was noted to be unaffected by type of NRT used
f Unadjusted RR estimated from data provided
g OR adjusted for recruitment centre
CAF no.a References Comparisonb Endpoint Casesc HR/RR/OR (95 % CI)d
3 Strandberg-Larsen et al. (2008) Any NRT versus no NRT Stillbirth 8/487 0.57 (0.28–1.16)e
13 Pollak et al. (2007) Any NRT + CBT versus CBT 
only
Fetal loss 3/2 0.77 (0.13–4.48)f
14 Oncken et al. (2008) Nicotine versus placebo gum Fetal loss 2/1 1.79 (0.17–19.44)f
Spontaneous abortion 2/0 4.49 (0.22–92.19)f
16 Coleman et al. (2012b) Nicotine versus placebo patch Miscarriage 3/2 1.52 (0.25–9.13)g
Stillbirth 5/2 2.59 (0.50–13.40)g
18 Berlin et al. (2014) Nicotine versus placebo patch Stillbirth 4/5 0.80 (0.22–2.94)f
Total fetal death 8/7 1.14 (0.42–3.09)f
Meta-analysis of stillbirth/fetal loss Fixed effect 0.78 (0.45–1.33)
Random effects 0.78 (0.45–1.33)
Heterogeneity p 0.51
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CI −0.5 to 0.6) weeks. Pollak et al. (2007) also reported 
results for small for gestational age, but based on very few 
cases.
Head circumference and infant length at birth (Table 6): 
No significant differences were seen in the two trials 
reporting results.
Preterm birth (Table 7): In one epidemiological study 
(Gaither et al. 2009) results reported relative to non-
smokers, for smokers who were or were not prescribed 
NRT in pregnancy have been converted to an OR within 
smokers. For consistency with other studies, the OR 
has been recalculated to compare effects of NRT within 
smokers. While this OR, 1.88 (0.97–3.56) is close to 
showing a significant increase in risk, no other result 
from the six clinical trials does so, one (Oncken et al. 
2008) giving a significantly reduced OR (0.39, 0.17–
0.91). A meta-analysis of the seven estimates showed 
no association, the random-effect estimate being 0.98 
(0.70–1.37).
Neonatal interim care admissions (Table 8): In the four 
clinical trials reporting findings no significant differences 
were seen, the overall random-effect estimate being 0.95 
(95 % CI 0.61–1.47),
Neonatal death (Table 9): The extremely limited data 
from two trials provides no indication of any major effect 
of NRT.
Table 4  Results summary for NRT and reproduction/development—birthweight or low birthweight
a CAF critical assessment form. CAF 4 is a prospective study, CAF 8 is a cross-sectional study, and the rest are clinical trials
b CBT cognitive behavioural therapy
c Exposed/unexposed cases. NA data not available. ‘–’ not applicable
d For differences in birthweight the mean is shown (exceptionally in one study exposure per week of NRT use), and for low birthweight the odds 
ratio (OR) or relative risk (RR) as indicated
e Birthweight was noted not to vary significantly by type of NRT used. Also using the Danish National Birth Cohort, Zhu et al. (2014) (CAF 7) 
reported a clear reduction in birthweight associated with maternal smoking, but no significant reduction associated with NRT use, regardless of 
whether the father smoked
f Adjusted OR in smokers estimated from data provided
g Unadjusted mean difference
h Unadjusted mean difference estimated from data provided
i Unadjusted RR estimated from data provided
j OR adjusted for recruitment centre
CAF no.a References Comparisonb Endpoint Casesc Statistic (95 % CI)d
4 Lassen et al. (2010) – Birthweight change (g) per 
week NRT use
– 0.25 (−2.31 to 2.81)e
8 Gaither et al. (2009) Prescribed/recommended NRT 
versus not
Low birthweight NA 1.49 (0.79 to 2.82)f
10 Wisborg et al. (2000) Nicotine versus placebo patch Birthweight difference (g) – 186 (35 to 336)g
Low birthweight 4/11 0.4 (0.1–1.1)i
13 Pollak et al. (2007) Any NRT + CBT versus CBT 
only
Birthweight difference (g) – −71 (−283 to 141)h
14 Oncken et al. (2008) Nicotine versus placebo gum Birthweight difference (g) – 337 (155 to 519)h
Low birthweight 2/16 0.11 (0.03–0.47)i
15 Swamy et al. (2009) Any NRT + CBT versus CBT 
only
Low birthweight 4/0 4.48 (0.25–81.63)i
16 Coleman et al. (2012b) Nicotine versus placebo patch Low birthweight 56/43 1.38 (0.90–2.09)j
17 El-Mohandes et al. (2013) Nicotine patch + CBT versus 
CBT only
Birthweight difference (g) – 206 (−98 to 510)h
Low birthweight 3/4 0.75 (0.19 to 3.03)i
18 Berlin et al. (2014) Nicotine versus placebo patch Birthweight difference (g) – 50 (−71 to 172)g
Low birthweight 27/33 0.82 (0.51–1.31)i
Meta-analysis of low birthweight (n = 7) Fixed effect 1.01 (0.78–1.31)
Random effects 0.81 (0.48–1.39)
Heterogeneity p p = 0.01
Weighted analysis of birthweight difference (n = 5) Mean 142 (−53 to 336)
Heterogeneity p p = 0.11
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Congenital abnormalities (Table 10): The two clinical tri-
als (Berlin et al. 2014; Coleman et al. 2012b) reported results 
only for any congenital abnormality, each finding a non-sig-
nificantly reduced risk based on quite few cases. An analysis 
based on the Danish National Birth Cohort (Morales-Suarez-
Varela et al. 2006) was unusual in only considering NRT 
users who did not smoke, not mentioning those who smoked 
and used NRT in pregnancy. Compared with those who nei-
ther smoked nor used NRT, the authors reported a marginally 
significant increased overall risk, with the adjusted relative 
rate given as 1.61 (95 % CI 1.01–2.58), which they sug-
gested “needs to be replicated”. The RRs listed in Table 10 
are based on comparison with smokers using NRT, this being 
non-significant 1.50 (0.94–2.41). A much larger UK study 
(Dhalwani et al. 2015) only reported results for major con-
genital abnormalities, but found no association with overall 
risk. Combining the estimate for this study with those for any 
congenital abnormality in the other studies gave a random-
effect estimate of 1.10 (0.86–1.41), which reduced to 1.02 
(0.81–1.28) if the result for non-smokers from the Danish 
cohort was excluded. Results by type of abnormality were 
only available from the two epidemiological studies. No sig-
nificant increase was seen for major musculoskeletal abnor-
malities in the Danish cohort, but the UK study reported a 
significant increase in respiratory system abnormalities (HR 
3.49, 95 % CI 1.40–8.71) though no significant effect of 
NRT for 10 other groupings. Commenting on the respiratory 
system finding, the authors noted “the statistical power was 
limited” and “higher morbidities in those women prescribed 
NRT may also be an explanatory factor”.
Apgar score (Table 11): Three clinical trials presented 
results for this measure of the health of a newborn child. 
Different metrics were used, but no significant NRT effect 
was seen.
Other endpoints for NRT and reproduction/development 
(Table 12): No significant relationships or consistent pat-
terns with NRT use were evident from the 10 publications 
providing results.
Authors’ conclusions varied as to whether NRT was 
harmful, beneficial or had no effect on reproduction and 
Table 5  Results summary for NRT and reproduction/development—gestational age/small for gestational age
a CAF critical assessment form. All studies are clinical trials
b CBT cognitive behavioural therapy
c For difference in gestational age the mean difference is shown, and for small for gestational age the relative risk (RR)
d Unadjusted mean difference estimated from data provided
e Unadjusted RR estimated from data provided; based on 4 exposed and 0 unexposed cases
f Unadjusted mean difference
CAF no.a References Comparisonb Endpoint Statistic (95 % CI)c
13 Pollak et al. (2007) Any NRT + CBT versus CBT 
only
Diff. in gestational age (wks) −0.7 (–1.6 to 0.2)d
Small for gestational age 4.64 (0.25–84.7)e
14 Oncken et al. (2008) Nicotine versus placebo gum Diff. in gestational age (wks) 0.9 (0.1–1.7)d
16 Coleman et al. (2012b) Nicotine versus placebo patch Diff. in gestational age (wks) 0.0 (−0.2 to 0.3)f
17 El-Mohandes et al. (2013) Nicotine patch + CBT versus 
CBT only
Diff. in gestational age (wks) 1.0 (0.16 to 1.84)d
18 Berlin et al. (2014) Nicotine versus placebo patch Diff. in gestational age (wks) −0.22 (−0.82 to 0.38)f
Weighted analysis of difference in gestational age (wks) Mean 0.1 (−0.5 to 0.6)
Heterogeneity p p = 0.34
Table 6  Results summary for NRT and reproduction/development—head circumference/length of infant
a CAF critical assessment form. Both studies are clinical trials
b Unadjusted mean difference estimated from data provided
c Unadjusted mean difference
CAF no.a References Comparison Endpoint (cm) Mean difference (95 % CI)
14 Oncken et al. (2008) Nicotine versus placebo gum Infant length 1.0 (−0.1 to 2.1)b
Head circumference 0.5 (−0.1 to 1.1)b
18 Berlin et al. (2014) Nicotine versus placebo patch Infant length 0.34 (−0.31 to 0.98)c
Head circumference −0.20 (−0.63 to 0.24)c
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development, though views expressed were often far from 
confident. Possible beneficial effects were concluded 
for three trials (El-Mohandes et al. 2013; Oncken et al. 
2008; Wisborg et al. 2000) based on increases in birth-
weight and/or gestational age in the NRT group. The large 
SNAP trial (Cooper et al. 2014b) also noted a beneficial 
effect on development at 2 years. Possible adverse effects 
were also noted, with the endpoints varying: overall con-
genital abnormalities (Morales-Suarez-Varela et al. 2006); 
infantile colic (Milidou et al. 2012); attention-deficit/
hyperactivity disorder (Zhu et al. 2014); low birthweight 
and preterm birth (Gaither et al. 2009); respiratory system 
abnormalities (Dhalwani et al. 2015); rapid fetal move-
ments (Kapur et al. 2001); and negative birth outcomes 
(Pollak et al. 2007). However, four of these conclusions 
(Gaither et al. 2009; Milidou et al. 2012; Morales-Suarez-
Varela et al. 2006; Zhu et al. 2014) were based on signifi-
cant differences from non-smokers, no longer significant 
Table 7  Results summary for NRT and reproduction/development—preterm birth
a CAF critical assessment form. CAF 8 is a cross-sectional study and the rest are clinical trials
b CBT cognitive behavioural therapy
c Exposed/unexposed cases
d OR odds ratio, RR relative risk
e RR adjusted for age, marital status, education and race/ethnicity; estimated from data provided
f Unadjusted RR
g Unadjusted RR estimated from data provided
h OR adjusted for recruitment centre
i Unadjusted OR
CAF no.a References Comparisonb Casesc OR/RR (95 % CI)d
8 Gaither et al. (2009) Prescribed/recommended NRT versus not 66/156 1.88 (0.97–3.56)e
10 Wisborg et al. (2000) Nicotine versus placebo patch 10/13 0.8 (0.4–1.7)f
13 Pollak et al. (2007) Any NRT + CBT versus CBT only 24/9 1.37 (0.68–2.75)g
14 Oncken et al. (2008) Nicotine versus placebo gum 7/16 0.39 (0.17–0.91)g
16 Coleman et al. (2012b) Nicotine versus placebo patch 40/45 0.90 (0.58–1.41)h
17 El-Mohandes et al. (2013) Nicotine patch + CBT versus CBT only 1/2 0.50 (0.05–5.18)g
18 Berlin et al. (2014) Nicotine versus placebo patch 27/26 1.03 (0.63–1.71)i
Meta-analysis (n = 7) Fixed effect 0.99 (0.78–1.26)
Random effect 0.98 (0.70–1.37)
Heterogeneity p 0.12
Table 8  Results summary for NRT and reproduction/development—neonatal intensive care admissions
a CAF critical assessment form. All studies are clinical trials
b CBT cognitive behavioural therapy
c Exposed/unexposed cases
d OR odds ratio, RR relative risk
e Unadjusted RR estimated from data provided
f OR adjusted for recruitment centre
g Unadjusted OR
CAF no.a References Comparisonb Casesc OR/RR (95 % CI)d
13 Pollak et al. (2007) Any NRT + CBT versus CBT only 15/3 2.57 (0.77–8.51)e
14 Oncken et al. (2008) Nicotine versus placebo gum 7/11 0.57 (0.23–1.41)e
16 Coleman et al. (2012b) Nicotine versus placebo patch 33/35 0.96 (0.58–1.57)f
18 Berlin et al. (2014) Nicotine versus placebo patch 12/14 0.85 (0.40–1.80)g
Meta-analysis (n = 4) Fixed effect 0.94 (0.66–1.35)
Random effects 0.95 (0.61–1.47)
Heterogeneity p 0.27
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when comparisons were made within smokers. Further-
more, one conclusion (Kapur et al. 2001) was based on a 
single case of rapid fetal movements in a subject given a 
placebo patch, while differences noted in the final study 
(Pollak et al. 2007) were not significant. The only study 
reporting significantly worse outcomes in smokers using 
(or allocated to) NRT than in other smokers was the 
increased incidence of major respiratory system congenital 
abnormalities (Dhalwani et al. 2015) and even here the 
authors noted “women prescribed NRT were consider-
ably more likely to have diagnosed morbidities, particu-
larly asthma and mental illnesses”. The remaining studies 
reported finding no effect, some for specific effects and 
some for a range of effects.
Except possibly for congenital abnormalities of the 
respiratory system (Dhalwani et al. 2015), the results in 
Table 9  Results summary 
for NRT and reproduction/
development—neonatal death
a CAF critical assessment form. Both studies are clinical trials
b Exposed/unexposed cases
c OR odds ratio, RR relative risk
d Unadjusted RR estimated from data provided
e Unadjusted OR estimated from data provided. This study also reported results for post-natal deaths, 
where based on one case in the NRT group, and one in the placebo, an unadjusted RR of 3.07 (0.12–75.4) 
can be estimated
CAF no.a References Comparisonb Casesc OR/RR (95 % CI)c
14 Oncken et al. (2008) Nicotine versus placebo gum 1/2 0.45 (0.04–4.86)d
16 Coleman et al. (2012b) Nicotine versus placebo patch 0/2 0.20 (0.01–4.24)e
Table 10  Results summary for NRT and reproduction/development—congenital abnormalities
a CAF critical assessment form. CAF 2 and CAF 9 are prospective studies and the rest are clinical trials
b MMS major musculoskeletal
c Exposed/unexposed cases
d OR odds ratio, RR relative risk
e Unadjusted relative prevalence rate estimated from data provided
f  Hazard ratios were presented adjusted for maternal age at conception, Townsend deprivation index score, and maternal diabetes, asthma, men-
tal illness and multiple births. Adjusted results were also presented for 11 other types of major congenital abnormality, but no significant differ-
ences were seen between groups
g OR adjusted for recruitment centre
h Unadjusted RR estimated from data provided
i Preferring any to major for CAF 2
j As relates to NRT use by non-smokers
CAF no.a References Comparison Endpointb Casesc RR/OR (95 % CI)d
2 Morales-Suarez-Varela et al. (2006) Any NRT, no smoking versus 
smoking no NRT
Any 19/3590 1.50 (0.94–2.41)e
Major 11/2890 1.02 (0.55–1.86)e
MMS 6/884 1.96 (0.86–4.45)e
9 Dhalwani et al. (2015) Prescribed versus not prescribed 
NRT
Major 90/314 1.07 (0.84–1.36)f
Respiratory system 10/10 3.49 (1.40–8.71)f
16 Coleman et al. (2012b) Nicotine versus placebo patch Any 9/13 0.70 (0.30–1.66)g
18 Berlin et al. (2014) Nicotine versus placebo patch Any 4/6 0.67 (0.19–2.33)h
Meta-analyses for congenital abnormalitiesi (n = 4) Fixed effect 1.10 (0.90–1.35)
Random effects 1.10 (0.86–1.41)
Heterogeneity p 0.34
Excluding CAF 2j (n = 3) Fixed effect 1.02 (0.81–1.28)
Random effects 1.02 (0.81–1.28)
Heterogeneity p 0.52
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Tables 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 show no evidence 
of a significantly poorer outcome in NRT users, whether 
in individual studies or in meta-analyses. Indeed, there is 
some evidence that allocation to NRT is associated with 
increased birthweight and gestational age at birth, and bet-
ter development of their offspring at 2 years. However, 
despite the quite large number of studies, the evidence has 
various limitations, including the few NRT exposed cases 
for some endpoints, the lack of dose–response data on dose 
or duration of use, the minimal data by type of NRT used, 
and the failure to adjust for extent and duration of cigarette 
smoking before NRT prescription, or extent of change in 
smoking following it.
For some more commonly studied conditions (fetal loss/
spontaneous abortion, birthweight/low birthweight, gesta-
tional age/small for gestational age, preterm birth, neonatal 
intensive care admissions and overall incidence of congeni-
tal abnormalities), where a lack of significant association 
was seen in meta-analyses, the data provide limited evi-
dence suggesting a lack of effect of NRT. Limited evidence 
of an effect is more appropriate for congenital abnormali-
ties of the respiratory system, where the observed posi-
tive association may result from confounding by increased 
morbidity in pregnant smokers allocated to NRT. For other 
endpoints considered (head circumference/length of infant, 
neonatal death and Apgar score), an assessment of inade-
quate evidence seems more appropriate for NRT.
Cardiovascular disease
The cardiovascular effects commonly observed with acute 
NRT use are an increase in heart rate, blood pressure 
and cardiac output (Benowitz and Gourlay 1997). These 
effects are physiological responses to nicotine’s activa-
tion of nAChRs, resulting in part from sympathetic neural 
stimulation and catecholamine release from the adrenal 
glands (Benowitz and Gourlay 1997; Klevans and Geb-
ber 1970). Because of the rapid development of tolerance 
to these physiological alterations, it seems unlikely that 
these acute effects play a significant role in cardiovascular 
disease (SAHE). In support of this statement, long-term 
(18–24 months) nicotine exposure (at levels observed in 
NRT users) does not appear to cause cardiovascular disease 
in experimental animals (Theophilus et al. 2012; Waldum 
et al. 1996; Wilson et al. 1938). In contrast, the short-term 
(≤12 weeks) administration of nicotine to animals has been 
shown to enhance or aggravate existing cardiovascular dis-
ease (i.e. chronic hypertension, atherosclerosis, myocardial 
ischaemia/reperfusion injury) in experimental models (Bui 
et al. 1995; Lau et al. 2006; Sridharan et al. 1985; Zhou 
et al. 2013). The results of these non-clinical studies sug-
gest the potential for serious cardiovascular adverse effects 
with nicotine exposure and support the need for a compre-
hensive review of studies investigating the presence of such 
SAHE in NRT users.
As summarized in Supplementary File 4, six epidemio-
logical studies (CAFs 21 to 26) provided relevant informa-
tion. One was a case–control study of MI (Kimmel et al. 
2001), one a case series analysis (Hubbard et al. 2005), one 
a prospective study of HIV-infected individuals (Elzi et al. 
2006) and three prospective studies of patients undergo-
ing cardiac procedures (Meine et al. 2005; Paciullo et al. 
2009; Woolf et al. 2012). Two studies (CAFs 24 and 25) 
were considered of “poor” study quality, the other four 
“fair”. Common weaknesses of these studies include few 
relevant events, short follow-up period and lack of control 
for confounders, including changes in smoking habits after 
starting NRT. Four clinical trials of patients with cardiac 
disease also provided relevant data (CAFs 27, 28A, 29 and 
30A). Three trials (Joseph et al. 1996; Rennard et al. 1994; 
Tzivoni et al. 1998) were double-blind RCTs of nicotine 
patches, ascribed a “low” risk of bias. The other (Mohi-
uddin et al. 2007), ascribed a “high” risk of bias, was less 
informative, only providing results relevant to the effects of 
an intensive intervention with individualized pharmacother-
apy, which only included NRT for some patients, results 
not being separately presented for those prescribed NRT. 
Note that one further clinical trial (Thomsen et al. 2010) 
Table 11  Results summary 
for NRT and reproduction/
development—Apgar score
a CAF critical assessment form. All studies are clinical trials
b OR odds ratio, RR relative risk
c The medians were identical in both the nicotine gum and placebo groups, for both the 1-min score (8) 
and the 5-min score (9). The p value derives from a Mann–Whitney U test
d OR adjusted for recruitment centre
e Unadjusted RR estimated from data provided
CAF no.a References Comparison Measure Test of differenceb
14 Oncken et al. (2008) Nicotine versus placebo gum 1-min median p = 0.62c
5-min median p = 0.061c
16 Coleman et al. (2012b) Nicotine versus placebo patch At 5 min <7 0.91 (0.45–1.80)d
18 Berlin et al. (2014) Nicotine versus placebo patch At 5 min <10 1.18 (0.54–2.57)e
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reported two cases of cardiovascular complications in those 
allocated to an intervention group including free supply 
of NRT and one in the control group, as part of a range of 
complications considered. Including those results, consid-
ered in the section on “Stroke”, would not have affected the 
conclusions for CVD. The studies provide results for vari-
ous endpoints, as considered below.
AMI (Table 13): Four studies (Joseph et al. 1996; Kim-
mel et al. 2001; Mohiuddin et al. 2007; Woolf et al. 2012), 
each based on less than 10 exposed cases, gave RRs (or 
ORs) less than 1.00, but not significantly so. Another study 
(Elzi et al. 2006), also on few cases, gave a significantly 
increased RR of 5.63 (95 % CI 1.07–29.64). This was based 
on an uncontrolled comparison of HIV patients participat-
ing (and not participating) in a smoking cessation program 
involving supply of NRT, data being presented show-
ing a substantial increase in history of CHD at baseline 
in the NRT exposed group. An analysis of a UK national 
Table 12  Results summary for NRT and reproduction/development—other endpoints
a CAF critical assessment form. CAFs 5 to 7 are prospective studies, and the rest are clinical trials, all controlled except for CAF 12
b CBT cognitive behavioural therapy
c AE adverse event, ADHD attention-deficit/hyperactivity disorder, HIS hypersensitivity inattention score. For most studies, the endpoint was 
recorded during or shortly after pregnancy. Exceptionally, CAF 5 collected data up to March 2006 and CAF 7 data up to August 2011 on births 
from 1996 to 2003, while CAF 20 followed births for 2 years
d Exposed/unexposed cases
e OR odds ratio, RR relative risk
f RR adjusted for year of birth, social class, maternal age at birth, maternal smoking dose, and maternal coffee and tea consumption. No signifi-
cant relationships were seen by type of strabismus
g OR adjusted for maternal age, parity, coffee consumption, alcohol consumption, binge drinking, and education/occupational status of couple. 
Estimated from data provided, restricted to smokers
h HR adjusted for maternal age, parity, alcohol intake during pregnancy, parental socio-economic status, parental psychopathology, and sex of 
child. Estimated from data provided, restricted to smokers
i Difference in mean HIS score for NRT use in smokers estimated from data provided. Adjusted for same variables as for ADHD (see footnoteh)
j Unadjusted RR estimated from data provided
k Unadjusted OR estimated from data provided
l OR adjusted for recruitment centre
CAF
no.a
References Comparisonb Endpointc Casesd OR/RR (95 %CI)e
5 Torp-Pedersen et al. 
(2010)
Any NRT versus no NRT Strabismus 61/1239 1.22 (0.92–1.61)f
6 Milidou et al. (2012) Any NRT versus no NRT Infantile colic 137/1417 1.15 (0.97–1.37)g
7 Zhu et al. (2014) Any NRT versus no NRT ADHD 29/532 1.11 (0.75–1.63)h
HIS NA −0.08 (−0.28 to 0.12)i
11 Kapur et al. (2001) Nicotine versus placebo patch Rapid fetal movements 0/1 0.24 (0.01–5.38)j
12 Schroeder et al. (2002) Nicotine patch Severe infant morbidity 3/− No comparison group
13 Pollak et al. (2007) Any NRT + CBT versus CBT 
only
Any serious AE 34/10 1.75 (0.93–3.28)j
Placental abnormality 4/0 4.64 (0.25–84.7)j
14 Oncken et al. (2008) Nicotine versus placebo gum Maternal hospitalization 9/8 1.01 (0.41–2.50)j
Spontaneous abortion 2/0 4.49 (0.22–92.19)j
Any serious AE 24/33 0.65 (0.42–1.01)j
16 Coleman et al. (2012b) Nicotine versus placebo patch Admission for pregnancy compli-
cation
44/41 1.10 (0.70–1.71)j
Any serious AE 9/6 1.53 (0.54–4.34)j
18 Berlin et al. (2014) Nicotine versus placebo patch Serious AE—mother 24/16 1.47 (0.81–2.68)j
Serious AE—fetus/newborn 13/14 0.93 (0.45–1.92)j
20 Cooper et al. (2014b) Nicotine versus placebo patch Infant death 2/2 1.00 (0.14–7.10)k
Definite development impairment 48/64 0.71 (0.48–1.06)l
Survival with no impairment 323/290 1.41 (1.05–1.87)l
Respiratory problems 132/111 1.28 (0.95–1.73)l
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database (Hubbard et al. 2005) based on 33,247 individuals 
prescribed NRT compared AMI incidence in the 56 days 
pre- and post-prescription with that in the period more than 
56 days from the prescription. The high RR of 5.55 (95 % 
CI 4.42–6.98) in the 56 days before NRT prescription 
suggests reverse causation, with NRT “being prescribed 
shortly after myocardial infarctions and strokes”, and is 
irrelevant to whether NRT might cause AMI. The lower 
RR of 1.27 (0.82–1.97) for the 56 days after prescription 
(which did not vary significantly by type of NRT) is more 
relevant. Excluding the high RR, the remaining estimates 
give a combined random-effect meta-analysis estimate of 
0.97 (0.55–1.71). Also omitting two studies not of NRT per 
se (Elzi et al. 2006; Mohiuddin et al. 2007), the estimate 
rises to 1.08 (0.75–1.56), but remains non-significant.
Mortality (Table 14): For the studies providing relevant 
results, the period following exposure varied, where stated, 
from 56 days to 2 years. Since the deaths were shortly after 
NRT exposure, and in all studies except one (Hubbard et al. 
2005) in patients with cardiac disease, most deaths were 
probably from CVD, though only Mohiuddin et al. (2007) 
give mortality results specifically for CVD. Although 
deaths in exposed cases were generally few, only exceed-
ing 10 in the case series analysis (Hubbard et al. 2005), 
the RRs were, with one exception, below 1.00, though 
only the RR of 0.23 (95 % CI 0.07–0.73) for the study of 
Table 13  Results summary for NRT and CVD–AMI
Note: no cases of AMI were reported in the clinical trials summarized in CAFs 27 and 29
a CAF clinical assessment form. CAF 21 is a case–control study, CAF 22A is a case series analysis, CAF 24 is a prospective study of individu-
als with HIV, CAF 26 is a prospective study of patients undergoing procedures for CVD, and CAFs 28A and 30A are clinical trials in patients 
with CVD
b Exposed/unexposed cases
c See CAF 21 for further ORs (all <1) according to smoking at time of patch use, confirmed (rather than any) AMI, timing of patch use and NRT 
use (rather than patch use)
d Adjusted estimate—see CAF for details of adjustment variables
e Relative incidence in the 56 days before the NRT prescription
f Relative incidence in the 56 days after the NRT prescription. There was no evidence of an increase in incidence for any formulation of NRT
g Unadjusted estimate
h Estimated from data provided
i Includes NRT prescription for some subjects
j Omitting first estimate from Hubbard et al. (2005)
CAF no.a References Comparison Endpoint Casesb RR/OR (95 % CI)
21 Kimmel et al. (2001) Used nicotine patch in week 
before MI versus did not 
use
MI 3/650 0.46 (0.09–1.47)c,d
22A Hubbard et al. (2005) 56 days before versus 
>56 days outside NRT 
prescription
MI 88/741 5.55 (4.42–6.98)d,e
56 days after versus 
>56 days outside NRT 
prescription
21/741 1.27 (0.82–1.97)d,f
24 Elzi et al. (2006) Provided NRT versus not MI within 1 year 2/4 5.63 (1.07–29.64)g
26 Woolf et al. (2012) Prescribed NRT versus not MI within 1 year 8/23 0.90 (0.40–2.06)d
28A Joseph et al. (1996) Nicotine versus placebo 
patch
MI or cardiac arrest within 
14 weeks
1/2 0.49 (0.04–5.41)g,h
30A Mohiuddin et al. (2007) Interventioni versus usual 
care
MI admission within 
2 years
9/17 0.49 (0.23–1.04)g,h
Meta-analysisi (n = 6) Fixed effects 0.99 (0.72–1.38)
Random effects 0.97 (0.55–1.71)
Heterogeneity p 0.07
Meta-analysisj omitting Elzi et al. (2006)  
and Mohiuddin et al. (2007) (n = 4)
Fixed effects 1.08 (0.75–1.56)
Random effects 1.08 (0.75–1.56)
Heterogeneity p 0.47
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intensive intervention versus usual care (Mohiuddin et al. 
2007) was significant at p < 0.05. The exception was the 
study of patients undergoing coronary artery bypass graft 
surgery (Paciullo et al. 2009), where the adjusted RR, 
estimated as 6.06 (1.65–22.21), was based on only three 
exposed cases (of 40 at risk) and one unexposed case (of 
489). Note that the unadjusted RR of 2.47 (0.74–8.32) was 
not significant, the reliability of adjusted analyses based 
on so few deaths being open to question. Random-effect 
meta-analysis showed no significant overall effect, the RR 
being 0.81 (95 % CI 0.41–1.60) based on all the studies and 
1.01 (0.51–1.98) omitting the trial of intensive intervention 
(Mohiuddin et al. 2007). Both analyses showed significant 
(p < 0.05) heterogeneity due to the single high estimate.
Admissions/readmissions (Table 15): Six studies pre-
sented results for admissions/readmissions overall or for 
various heart-related reasons. Numbers of exposed cases 
tend to be greater than in Tables 13 and 14. Of 15 estimates, 
five are above 1.00 and 10 below. The only two significant 
at p < 0.05 were decreases seen in the trial of intensive 
intervention (Mohiuddin et al. 2007). Due to the variety of 
endpoints, and the few estimates for any, meta-analysis has 
not been conducted.
Other endpoints (Table 16): Two clinical trials presented 
relevant results, though numbers of exposed cases are often 
quite low. Of the six effect estimates, one is above and five 
below 1.00, with none close to statistically significant (at 
p < 0.05). In contrast, the study of HIV-infected individuals 
Table 14  Results summary for NRT and CVD—Mortality
Note: no deaths were reported in the clinical trials summarized in CAFs 27 and 29
a CAF clinical assessment form. CAF 22A is a case series analysis, CAFs 23, 25 and 26 are prospective studies of patients undergoing proce-
dures for CVD, CAF 24 is a prospective study of individuals with HIV and CAFs 28A and 30A are clinical trials in patients with CVD
b Exposed versus unexposed cases
c Adjusted estimate—see CAF for details of adjustment variables
d Mortality rates were also non-significantly lower for patch for 7-day and 30-day mortality
e Estimated from data provided
f Unadjusted estimate
g Deaths due to lung cancer or HIV-related not considered
h No reliable OR estimate could be made, the comparison being of 0/34 with 1/383
i Follow-up period not stated
j Compared to smokers not prescribed NRT; the RR versus non-smokers being 6.17 (1.62–23.69)
k Includes NRT prescription for some subjects
l Using all cause estimate from Mohiuddin et al. (2007)
CAF no.a References Comparison Endpoint Casesb RR (95 % CI)
22A Hubbard et al. (2005) 56 days before versus 
>56 days outside NRT 
prescription
Mortality 33/− 0.86 (0.60–1.23)c
56 days after versus >56 days 
outside NRT prescription
23 Meine et al. (2005) Prescribed nicotine patch 
versus not
1-year mortalityd 9/10 0.90 (0.37–2.16)e,f
24 Elzi et al. (2006) Provided NRT versus not 1-year CVD mortalityg 0/1 Not estimatedh
25 Paciullo et al. (2009) Used nicotine patch versus not Mortalityi 3/1 6.06 (1.65–22.21)c,j
26 Woolf et al. (2012) Prescribed NRT versus not 1-year mortality 7/24 0.80 (0.33–1.91)c
28A Joseph et al. (1996) Nicotine versus placebo patch 14-week mortality 1/6 0.16 (0.02–1.36)e,f
30A Mohiuddin et al. (2007) Interventionk versus usual care 2-year mortality
All causes 3/12 0.23 (0.07–0.73)c
CVD 3/9 0.31 (0.09–1.10)e,f
Meta-analysisl Fixed effect 0.84 (0.63–1.13)
Random effects 0.81 (0.41–1.60)
Heterogeneity p 0.007
Meta-analysis omitting Mohiuddin et al. (2007) Fixed effect 0.92 (0.68–1.24)
Random effects 1.01 (0.51–1.98)
Heterogeneity p 0.027
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(Elzi et al. 2006) gave an RR of 7.51 (95 % CI 1.30–43.41) 
for undergoing coronary angioplasty. However, as for AMI, 
the analysis took no account of the much higher baseline 
history of CVD in the group given NRT.
Conclusions reached by the authors on NRT and CVD 
were generally not specific to an endpoint. Two (El-
Mohandes et al. 2013; Kimmel et al. 2001) were quite 
positive that NRT (or intensive intervention) had a benefi-
cial effect, while most authors simply argued no effect was 
demonstrated. The exception was Paciullo et al. (2009), 
who noted the significant increase in mortality, but com-
mented that “additional evaluation in large patient cohorts 
with prospective controls is warranted”.
Except possibly for findings from two “poor” qual-
ity studies (Elzi et al. 2006; Paciullo et al. 2009), based 
on few exposed cases, the overall evidence suggests NRT 
is not associated with any increased CVD risk. However, 
it cannot be regarded as conclusive of a lack of effect. 
Limitations of the evidence include small numbers of 
exposed cases in most studies, some analyses not relat-
ing to actual use of NRT, the short follow-up period, the 
absence of dose–response data, and the failure to adjust for 
smoking either before or after NRT prescription. We con-
clude there is limited evidence suggesting a lack of effect 
concerning the relationship of NRT use to the risk of CVD.
Stroke
NRT product warning label statements indicate a poten-
tial health risk to NRT users with high blood pressure (US 
Food and Drug Administration 2015a). Such warnings sug-
gest a potential risk of stroke with NRT or nicotine expo-
sure. In fact, several animal studies support a potential role 
for nicotine in increasing cerebral microvessel thrombo-
sis (Fahim et al. 2014) and inhibiting restoration of brain 
microvascular flow (Wang et al. 1997) in experimental 
Table 15  Results summary for NRT and CVD—Admissions/readmissions
a CAF clinical assessment form. CAFs 23, 25 and 26 are prospective studies of patients undergoing procedures for CVD, CAF 24 is a prospec-
tive study of individuals with HIV, and the rest clinical trials in patients with CVD
b Follow-up periods were CAFs 23 and 26 1 year, CAF 27 5 weeks, CAF 28A 14 weeks, CAF 29 2 weeks and CAF 30A 2 years
c Exposed/unexposed cases
d Estimated from data provided
e Adjusted estimate—see CAF for details of adjustment variables
f For angina, congestive heart failure, or arrhythmia
g One for chest pain resulting in bypass surgery, one for non-CVD reasons attributed to nicotine withdrawal
h Unadjusted
i Includes NRT prescription for some subjects
j Including AMI
CAF no.a References Comparison Endpointb Casesc RR (95 % CI)
23 Meine et al. (2005) Prescribed nicotine patch Coronary bypass 37/26 1.42 (0.90–2.25)d
Coronary angioplasty 94/79 1.19 (0.95–1.48)d
26 Woolf et al. (2012) Prescribed NRT versus not Repeat revascularization 18/58 0.77 (0.44–1.36)e
Hospitalizationf 41/104 1.01 (0.66–1.53)e
27 Rennard et al. (1994) Prescribed nicotine patch versus 
not
Hospitalization 0/2f 0.21 (0.01–4.20)d,h
28A Joseph et al. (1996) Nicotine versus placebo patch Increased severity of angina 7/10 0.69 (0.27–1.79)d,h
Arrhythmia 5/3 1.64 (0.40–6.82)d,h
Congestive heart failure 2/2 0.99 (0.14–6.96)d,h
Outpatient visit for increased severity of 
atherosclerotic CVD
12/7 1.69 (0.68–4.23)d,h
29 Tzivoni et al. (1998) Nicotine versus placebo patch Bypass surgery 0/1 0.35 (0.01–8.31)d,h
30A Mohiuddin et al. 
(2007)
Interventionh versus usual care Admission for:
Any causei 25/41 0.56 (0.37–0.84)d
CVD 20/37 0.50 (0.31–0.79)d,h
Unstable angina 8/14 0.52 (0.23–1.20)d,h
Cardiac arrhythmia 1/2 0.46 (0.04–4.98)d,h
Decompensated heart failure 2/4 0.46 (0.09–2.45)d,h
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models of thromboembolic injury and repair (as compared 
to vehicle controls without nicotine). Three published stud-
ies from separate laboratories (Bradford et al. 2011; Paul-
son et al. 2010; Wang et al. 1997) also investigated the 
impact of nicotine exposure on cerebral ischaemia/reperfu-
sion injury in experimental animal models. Similar to the 
findings observed for myocardial ischaemia/reperfusion 
injury, short-term nicotine exposure increased cerebral 
infarct size. Based on findings from non-clinical studies 
described above, we evaluated epidemiological studies and 
clinical trials for an association between stroke and NRT 
use.
Only three studies (Hubbard et al. 2005; Joseph et al. 
1996; Panos et al. 2010) provide information on NRT and 
stroke, fuller details being presented in CAFs 22B, 28B and 
31. The first (Hubbard et al. (2005), study quality “fair”) 
was the case series analysis which also reported results 
on CVD and suffers from weaknesses noted above. The 
second (Joseph et al. (1996), risk of bias “low”) was the 
clinical study of patients with cardiac disease also report-
ing results for CVD and other SAHEs. The third (Panos 
et al. (2010), study quality “fair”) was a prospective study 
of patients admitted to an intensive care unit with a neuro-
logical insult. Note that one study (Carandang et al. 2011) 
which reported on the relationship between patch use and 
various adverse health effects in subarachnoid haemor-
rhage patients is considered in the section below on “Other 
SAHEs in patients”.
Table 17 summarizes the main results. The high RR 
(compared to baseline levels) of 3.59 (95 % CI 2.56–5.03) 
in the 56 days before NRT prescription for the case series 
analysis (Hubbard et al. 2005) suggests reverse causation 
and is irrelevant to whether NRT can cause strokes. The 
lower RR of 1.30 (0.77–2.19) for the 56 days after prescrip-
tion is more relevant. There was no evidence of an effect of 
NRT in the 56 days post-prescription in subgroups by sex, 
age, previous history of angina or hypertension, or by type 
of NRT used, nor when analyses were repeated using sec-
ond stroke as the outcome. An RR of 2.47 (1.16–5.24) in 
days 43–56 after prescription was regarded by the authors 
as an “isolated increase”, no evidence of an increased risk 
being seen for days 1–14, 15–28 or 29–42. No evidence of 
an effect of NRT was seen in the small clinical trial (Joseph 
et al. 1996) or in the study of neurological patients (Panos 
et al. 2010). None of the authors of the three publications 
claimed any adverse effect on stroke had been established.
While the results provide no clear evidence of any 
increased risk of stroke, one cannot regard the findings as 
conclusive of a lack of effect. This is because of the few 
publications and cases of stroke post-NRT and various 
study weaknesses. We consider there is inadequate evi-
dence concerning the relationship of NRT to stroke.
Other SAHEs in patients
NRT product warning label statements (health-related) 
indicate potential risk to users with gastrointestinal (GI) 
conditions (such as stomach ulcers) and diabetes. For dia-
betes, several human studies demonstrate nicotine exposure 
results in enhanced insulin resistance in type 2 diabetics 
Table 16  Results summary for NRT and other CVD endpoints
a CAF clinical assessment form. CAF 24 is a prospective study of individuals with HIV and the other two clinical trials in patients with CVD
b Follow-up periods were CAF 24 1 year, CAF 27 5 weeks and CAF 29 2 weeks
c Exposed/unexposed cases
d All estimates were unadjusted and estimated from data provided
e Of various types, mainly age related, none significantly increased in the exposed group
f Data at weeks 2, 3 and 4 also showed no significant difference
g Of various types, none significantly increased in the exposed group
h All relating to angina
i No significant treatment differences were seen in relation to timing or total number of episodes
CAF no.a References Comparison Endpointb Casesc RR/OR (95 % CI)d
24 Elzi et al. (2006) Provided NRT versus not Underwent percutaneous transluminal coro-
nary angioplasty
2/3 7.51 (1.30–43.41)
27 Rennard et al. 
(1994)
Provided nicotine patch versus 
not
Premature termination due to adverse 
eventse
3/8 0.38 (0.11–1.40)
Angina at week 1 8/13 0.63 (0.28–1.44)
Angina at week 5f 5/7 0.73 (0.24–2.21)
Clinically important ECG changesg 22/26 0.87 (0.54–1.39)
29 Tzivoni et al. (1998) Nicotine versus placebo patch Serious adverse experiencesh 2/1 2.08 (0.19–22.22)
Ischaemic episodesi 17/25 0.71 (0.44–1.15)
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but not in healthy individuals (Axelsson et al. 2001; Epi-
fano et al. 1992). For example, a study from Axelsson and 
co-workers investigated the effects of acute intravenous 
nicotine infusion on insulin sensitivity in non-smoker type 
2 diabetics versus healthy non-smoker controls. While sub-
jects with type 2 diabetes were more insulin resistant than 
healthy controls at baseline, nicotine infusion significantly 
decreased insulin sensitivity in type 2 diabetics but did not 
modify the insulin response in controls (Axelsson et al. 
2001). In addition to diabetes, studies using well-known 
experimental models for peptic ulcer formation, pancreatic 
injury and renal injury have also demonstrated that short-
term nicotine exposure has the potential to aggravate all of 
these pathological conditions (Arany et al. 2011; Chowd-
hury et al. 1995; Qiu et al. 1991; Wong et al. 2002). There-
fore, based on findings from clinical and non-clinical stud-
ies described above, we evaluated epidemiological studies 
and clinical trials for an association between NRT use and 
other SAHEs such as diabetes, peptic ulcer, pancreatitis 
and renal effects.
As summarized in Supplementary File 5, one epidemio-
logical study (Carandang et al. 2011) and four clinical trials 
(Joseph et al. 1996; Lee et al. 2013; Mohiuddin et al. 2007; 
Thomsen et al. 2010) of patients provide information relat-
ing NRT and other SAHEs not generally related to cancer 
or CVD. Further details are presented in CAFs 28C, 30B, 
32, 33 and 34. The epidemiological study (Carandang et al. 
2011), in patients with subarachnoid haemorrhage, was 
ascribed study quality “fair”. Three clinical trials (Lee et al. 
2013; Mohiuddin et al. 2007; Thomsen et al. 2010) were 
ascribed a “high” risk of bias for only providing results for 
an intervention which included use of NRT (not necessar-
ily in all patients), the results possibly reflecting possible 
effects of intervention rather than of NRT. The other trial 
(Joseph et al. 1996), which did allocate patients to NRT, 
was ascribed risk of bias “low”. Common weaknesses 
include the small number of relevant events, the rela-
tively short follow-up period and the failure to control for 
changes in smoking habits following starting NRT. A vari-
ety of endpoints were considered, including complications 
following surgery and readmissions to hospital.
The main results are summarized in Table 18, some 
further results being given in the CAFs. The only signifi-
cant (p < 0.05) differences noted in relation to NRT use 
(or intervention) were for clinical vasospasm and poor out-
come in the study of subarachnoid haemorrhage patients 
(Carandang et al. 2011), which was less frequent (OR 0.46, 
95 % CI 0.25–0.84) in patients using patches. Total length 
of stay in hospital was also significantly shorter in patch 
users in this study (see CAF 32). There was no significant 
adverse effect of NRT use (or intervention) for any other 
endpoint. The authors generally agreed in regarding the 
results as not demonstrating an adverse effect of NRT for 
intervention.
The available evidence does not indicate any effect of 
NRT. However, this cannot be regarded as conclusive due 
Table 17  Results summary for NRT and stroke
a CAF clinical assessment form. CAF 22B is a case series analysis, CAF 31 is a prospective study of patients undergoing neurological proce-
dures and CAF 28B is a clinical trial in patients with CVD
b Exposed/unexposed cases
c Adjusted estimate—see CAF for details of adjustment variables
d Relative incidence in the 56 days before the NRT prescription
e Relative incidence in the 56 days after the NRT prescription. There was no evidence of an increase in incidence for any formulation of NRT
f Follow-up period unclear
g Unadjusted
h As the study followed up patients admitted to an intensive care unit for a neurological insult, many of these are likely to be stroke-related
i The authors noted that the association was considerably weakened after adjustment for subarachnoid haemorrhage at baseline
CAF no.a References Comparison Endpoint Casesb RR/OR (95 % CI)
22B Hubbard et al. 
(2005)
56 days before versus >56 days outside 
NRT prescription
Stroke 39/444 3.59 (2.56–5.03)c,d
56 days after versus >56 days outside 
NRT prescription
15/444 1.30 (0.77–2.19)c,e
31 Panos et al. (2010) Given NRT versus not given Ischaemic strokef 3/6 0.50 (0.13–1.93)g
Deathf,h 5/6 0.83 (0.26–2.63)g
Vasospasmf 23/12 1.90 (0.99–3.63)g
Unfavourable dischargef 48/37 1.29 (0.91–1.87)g
28B Joseph et al. (1996) Nicotine versus placebo patch Admission within 14 weeks for cer-
ebrovascular disease
4/3 1.32 (0.30–5.82)g,i
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to the weaknesses noted above. We conclude there is inad-
equate evidence concerning the relationship of NRT to the 
risk of the SAHEs considered here.
Other SAHEs, mainly in healthy populations
As summarized in Supplementary File 6, four meta-analy-
ses (Greenland et al. 1998; Mills et al. 2010; Moore et al. 
2009; Stead et al. 2012) provided relevant results, more 
details being given in CAFs 35–38. Most studies considered 
in the meta-analyses were of trials conducted in healthy 
populations, but some were of patients with specified con-
ditions. Three meta-analyses (Greenland et al. 1998; Moore 
et al. 2009; Stead et al. 2012) limited attention to RCTs, 
the other (Mills et al. 2010) also including results of obser-
vational studies. One meta-analysis (Moore et al. 2009) 
was limited to RCTs of smokers declaring no intention to 
quit, concerned smoking reduction and involved only seven 
RCTs. The other meta-analyses concerned smoking cessa-
tion studies and involved far more studies, the more recent 
meta-analyses (Mills et al. 2010; Stead et al. 2012) com-
bining data from over 100 studies. For two meta-analyses 
(Greenland et al. 1998; Mills et al. 2010), adverse events 
were clearly the central interest. However, one (Moore 
et al. 2009) was mainly concerned with efficacy and safety, 
and another (Stead et al. 2012) with smoking cessation, 
both giving very limited results for adverse events.
The main findings of the four meta-analyses are sum-
marized in Table 19. Where prevalences were only given 
for the NRT groups, these are noted in CAF 37, but not 
included in Table 19, nor considered further here. As listed 
in Table 19, no significant relationships between NRT and 
Table 18  Results summary for studies in patients on NRT and other serious health effects
a CAF clinical assessment form. CAF 32 is a prospective study of patients with a subarachnoid haemorrhage, CAFs 28C and 30B are clinical 
trials in patients with CVD, while CAFs 33 and 34 are clinical trials of surgical patients
b Follow-up periods were 14 weeks for CAF 28C and 2 years for CAF 30. For CAFs 32, 33 and 34, the periods were not clearly defined but 
results mainly relate to the period before, or shortly after, hospital discharge
c Exposed/unexposed cases
d Unadjusted
e Estimated from data provided
f Adjusted estimate—see CAF for details of adjustment variables
g Includes supply of NRT
h It was not made clear what period this related to
i Also includes respiratory and cardiovascular complications, urinary tract infection, nausea and vomiting and other complications
CAF no.a References Comparison Endpointb Casesc RR/OR (95 % CI)
32 Carandang et al. (2011) Prescribed nicotine patch versus 
not
Mortality 2/12 0.36 (0.07–1.43)d,e
Angiographic vasospasm 39/90 0.85 (0.65–1.12)d,e
Clinical vasospasm 17/56 0.45 (0.23–0.88)f
Poor outcome 16/64 0.46 (0.25–0.84)f
28C Joseph et al. (1996) Nicotine versus placebo patch Admission for peripheral vascular 
disease
3/5 0.59 (0.14–2.45) d,e
Admission for other reasons 16/13 1.21 (0.59–2.48)d,e
30B Mohiuddin et al. 
(2007)
Interventionf versus usual care Non-CVD mortality 0/3 Not significantd
Non-cardiac hospitalizations 5/4 1.15 (0.32–4.15)d,e
33 Lee et al. (2013) Interventionf versus usual care Complications
 Interoperative 5/6 0.83 (0.27–2.6)d
 Post-operative (immediate) 2/5 0.39 (0.08–2.0)d
 Any timeh 11/14 0.79 (0.38–1.63)d
 In 30-day follow-up 12/8 1.40 (0.61–3.2)d
Unanticipated hospital admission 2/2 0.98 (0.14–6.8)d
Unscheduled visit during post-operative 
period
16/9 1.66 (0.78–3.6)d
34 Thomsen et al. (2010) Interventionf versus not Any wound complication 25/28 0.97 (0.65–1.45)d
Any complicationi 38/35 1.00 (0.73–1.33)d
Secondary surgery 1/0 Not significante
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any health effect were reported in the earliest meta-analy-
sis (Greenland et al. 1998), based on quite low total inci-
dences, or in the meta-analysis of smoking reduction stud-
ies (Moore et al. 2009). However, the recent meta-analyses 
(Mills et al. 2010; Stead et al. 2012), no doubt based on 
sets of studies which overlap considerably, both reported a 
significant (p < 0.01) approximate doubling of risk of heart 
palpitations and chest pains in subjects allocated to NRT. 
Mills et al. (2010) noted that the increased risk was evident 
both for patches and orally administered NRT and refer to 
high nicotine concentrations in the serum of NRT users 
who continue to smoke, and pre-existing CVD as possible 
explanations for the association.
The first two reviews saw no evidence of harm from 
NRT. However, the third review (Mills et al. 2010) noted 
that “The use of NRT is associated with a variety of side 
effects”. However, the side effects referred to, for example, 
nausea and insomnia are generally not considered serious. 
Even heart palpitations and chest pains are not generally 
considered SAHEs (Little and Ebbert 2015; Stead et al. 
2012; US Food and Drug Administration 2015a). In agree-
ment, the final review (Stead et al. 2012) noted that “there 
is no evidence that NRT increases the risk of heart attacks”. 
Commenting on the results for heart palpitations and chest 
pains, they stated “this is potentially the only clinically sig-
nificant serious adverse event to emerge from the trials and 
constitutes an extremely rare event, occurring at a rate of 
2.5 % in the NRT groups compared with 1.4 % in the con-
trol groups in the 15 trials in which it was reported at all”.
The third review (Mills et al. 2010) points out various 
relevant limitations, which apply generally: “These include 
limitations of the primary studies themselves as well as 
Table 19  Results of meta-analyses of NRT and other serious adverse health effects
a CAF clinical assessment form
b The RR (95 % CI) per 21 mg nicotine was given as 1.43 (0.48–4.24)
c The RR (95 % CI) per 21 mg nicotine was given as 1.79 (0.50–6.45)
d The RR (95 % CI) per 21 mg nicotine was given as 2.12 (0.62–7.27)
e No significant differences in RR were noted by type of NRT used
f None judged likely to be due to treatment
g Both patches and oral NRT were associated with an increased risk
h This was an attempt to replicate the findings of Mills et al. (2010). Otherwise the authors made no systematic attempt to synthesize quanti-
tatively the incidence of the various side effects reported with the different NRT preparations. This was because of the extensive variation in 
reporting the nature, timing and duration of symptoms
CAF no.a References Endpoint Exposed  % (n) Unexposed  % (n) RR (95 % CI)
35 Greenland et al. (1998) AMI 0.8 (3) 0.8 (3) 1.00 (0.17–5.83)
Stroke 0.3 (1) 0.6 (2) 0.54 (0.02–6.73)
Tachycardia 0.8 (2) 0.0 (0) Not significant
Palpitations 0.4 (2) 1.8 (8) 0.26 (0.04–1.10)
Angina 0.4 (1) 0.4 (1) 1.00 (0.03–39.0)
Arrhythmia 2.7 (11) 2.2 (9) 1.26 (0.56–2.87)b
Hypertension 2.3 (8) 1.4 (5) 1.60 (0.52–5.48)c
Asthma 0.0 (0) 1.7 (2) Not significant
Bronchitis 7.8 (9) 4.2 (5) 1.91 (0.63–6.54)d
Urogenital symptoms 0.0 (0) 0.8 (1) Not significant
Neurological symptoms 3.5 (4) 0.6 (1) 3.80 (0.51–10.6)
36 Moore et al. (2009) Death 0.3 (4) 0.3 (4) 1.00 (0.25–4.02)e
Serious adverse eventf 7.7 (86) 7.1 (79) 1.09 (0.79–1.50)e
Discontinued because of adverse 
event
1.7 (19) 1.3 (15) 1.27 (0.64–2.51)e
37 Mills et al. (2010) Death 0.8 (11) 1.2 (16) 0.74 (0.33–1.67)
Heart palpitations and chest pains 3.0 (189) 1.6 (64) 2.06 (1.51–2.82)g
Serious adverse events “25 RCTs reported serious adverse events occurring but none 
were statistically significant (data not shown)”
38 Stead et al. (2012) Heart palpitations and chest painsh 2.5 (167) 1.4 (62) 1.88 (1.37–2.57)
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those associated with combining results across potentially 
heterogeneous studies or populations. The main limitation 
of the primary studies is the mechanism by which adverse 
events are recorded. In the majority of instances this would 
be through passive reporting and therefore be susceptible 
to the underreporting associated with such techniques”. 
Nevertheless, the magnitude and significance of the asso-
ciation of NRT use in RCTs with the reported incidence of 
heart palpitations and chest pains strongly suggest a causal 
relationship, though whether this increased risk is limited 
to patients with pre-existing CVD is unclear from the avail-
able evidence. There appears to be sufficient evidence of a 
relationship between NRT and the incidence of heart palpi-
tations and chest pains, but these outcomes are not consid-
ered SAHEs. For SAHEs, however, the data can generally 
be regarded as limited evidence suggesting a lack of effect 
of NRT, though for the more rarely seen conditions inad-
equate evidence seems a more appropriate assessment.
Discussion
For many endpoints considered, the evidence presented 
is clearly inadequate to reach a reliable conclusion on 
whether NRT has an effect. This includes cancer, stroke, 
the serious health effects in patients considered in Table 18 
and some of the less commonly considered reproduction/
development endpoints. For some more commonly studied 
reproduction/development endpoints (including fetal loss, 
spontaneous abortion, birthweight, prematurity, neonatal 
intensive care admissions, overall incidence of congeni-
tal abnormalities and ADHD) and also for CVD, the evi-
dence available suggests a lack of effect of NRT. Only for 
two endpoints is there any apparent evidence of harm. One, 
only providing limited evidence, given the association may 
result from confounding by higher morbidities in women 
prescribed NRT, is congenital abnormalities of the respira-
tory system where an increased incidence associated with 
NRT was seen in one study (Dhalwani et al. 2015). The 
other is heart palpitations and chest pains where a signifi-
cant doubling of risk was reported in two recent meta-anal-
yses of evidence from randomized controlled studies (Mills 
et al. 2010; Stead et al. 2012), which we regard as sufficient 
evidence of an effect, though it is not a SAHE.
Limitations
Numerous limitations affect the available evidence on pos-
sible adverse health risks from NRT use. First consider the 
evidence from the clinical trials. These typically compare 
a defined group of smokers allocated to receive NRT or a 
placebo and are designed to investigate effects of allocation 
on cessation rates. For any given outcome, there are three 
possible results, a significant increase in risk of a SAHE, a 
significant decrease in risk, or no significant change.
Interpreting a significant increase in risk seems rela-
tively straightforward. Unless due to chance, to confound-
ing (unlikely to be relevant in an RCT) or to an effect of 
smoking withdrawal in smokers who quit as a result of 
using NRT, it provides direct evidence of an effect of NRT.
The finding of no significant difference in risk can have 
various interpretations. One obvious possibility is the 
study was too small, particularly likely for relatively rare 
outcomes, since clinical studies are generally powered to 
detect effects on cessation, not on health outcomes. A sec-
ond possibility is that actual usage of NRT was only for 
a very limited period. A third is that the follow-up period 
may have been too short. Especially for chronic diseases, 
risks may, for some time, depend predominantly on past 
exposure, before allocation to NRT.
The finding of a significant decrease in risk of a SAHE 
in the NRT group can also have various interpretations and 
is hindered by the lack of corresponding results for never 
smokers. Thus, the endpoint may be related to components 
of smoke other than nicotine, with the observed reduction 
due to greater quitting in the NRT group. Alternatively, the 
endpoint may be increased by nicotine exposure, with the 
reduced risk due to the reduced dose of nicotine, either as 
a result of increased quitting in the NRT group, or to the 
NRT delivering less nicotine than cigarettes.
There are also other issues which limit interpreta-
tion. For instance, some studies are of a general cessation 
intervention including NRT, and not just of NRT, so risk 
differences may result from other aspects of the interven-
tion. Also, some studies involve a group prescribed or rec-
ommended NRT, with many subjects possibly ignoring the 
advice and never using NRT. Another issue is that the anal-
yses typically compare the groups initially allocated (as 
“intention-to-treat” analyses), not distinguishing risks in 
those who quit, cut down, or continue to smoke as before. 
Nor do they distinguish events in periods where the sub-
jects were still using NRT and in those where they had quit. 
Also, there is very little information on risk by type of NRT 
used, or on dose–response, with results not related to the 
prescribed NRT dose. Finally, there is inconsistent report-
ing of adverse events, with differing classifications in dif-
ferent studies.
Turning now to epidemiological studies, a major issue 
is confounding by other variables, which affect risk of an 
SAHE and differ between the NRT and non-NRT groups. 
However, epidemiological studies can provide results 
for never smokers, or for those who both smoke and use 
NRT, and a few studies do adjust for changes in smoking 
post-NRT. If NRT users have no significant excess risk 
compared to non-smokers, then this suggests no effect of 
NRT, though issues of power and confounding remain. If, 
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alternatively, similar increases are seen in NRT users and 
smokers, then this may mean risks are nicotine-related, 
with the dose of nicotine being unchanged. However, it 
may also mean the study was too small or too short term 
to detect differences in risk of an outcome resulting from 
chronic exposure. An increase in risk in the NRT group, but 
less than in smokers, could be because quitting reduces the 
dose of nicotine, or of other tobacco components. Clearly, 
the overall evidence is limited, with some findings difficult 
or impossible to interpret reliably in terms of an effect (or 
lack of effect) of NRT.
Comparison with Reproductive/Developmental Reviews
It is interesting to compare our findings with those of some 
of the reviews we identified. The first, published in 2008, 
was mainly concerned with effects of smoking (Rore et al. 
2008) and included little on possible health effects of NRT, 
though it mentioned one study (Wisborg et al. 2000) as 
providing evidence “that nicotine as present in NRT prod-
ucts does not have an adverse effect on infant weight”, and 
another (Kapur et al. 2001) as suggesting that rapid fetal 
movements seen in a single pregnant woman may have 
been due to nicotine withdrawal. Another review, concern-
ing the role of pharmacotherapy for smoking cessation, was 
published in 2009 (Oncken and Kranzler 2009). Again, no 
clear conclusions were drawn, most attention being given 
to NRT use possibly leading to an increase in birthweight. 
They considered the higher congenital malformation rates 
compared to non-smokers in the Danish Birth Cohort Study 
(Morales-Suarez-Varela et al. 2006) “should be interpreted 
with caution” and also noted the lack of relationship with 
stillbirth (Strandberg-Larsen et al. 2008).
In 2010, two reviews were published. One, which con-
cerned long-term consequences of fetal and neonatal nico-
tine exposure (Bruin et al. 2010), evaluated evidence from 
six studies we considered (see CAFs 2, 3, 8, 10, 13 and 
14), but reached no overall conclusions, except that “the 
safety of NRT use during pregnancy has been evaluated in 
a limited number of short-term human trials, but there is 
currently no information on the long-term effects of devel-
opmental nicotine exposure in humans”. The other, “nico-
tine replacement therapy effect on pregnancy outcomes” 
(Forinash et al. 2010), considered five of the studies (CAFs 
2, 10, 12, 13, 14), the authors concluding that “if behaviour 
modification therapy is attempted without success, NRT 
should be offered because of decreased risk of low birth-
weight and preterm delivery compared to continued smok-
ing. Additionally, NRT does not appear to increase the risk 
of malformations”.
Two further reviews, in 2011 and 2012, were both by 
the same group. The first (Coleman et al. 2011) concerned 
efficacy and safety of NRT for smoking cessation during 
pregnancy, while the second (Coleman et al. 2012a) was 
a Cochrane review of pharmacological interventions for 
promoting smoking cessation during pregnancy. The first 
review (Coleman et al. 2011) considered five RCTs, one 
(Hotham et al. 2006) giving no relevant safety results, 
the other four considered in CAFs 10, 11, 13 and 14. The 
authors concluded “there is currently insufficient evidence 
to determine whether or not nicotine replacement therapy 
is effective or safe when used in pregnancy for smok-
ing cessation; further research and, in particular, placebo-
randomized controlled trials are required”. The Cochrane 
review was also restricted to RCTs, considering one addi-
tional trial (CAF 16). The conclusion was essentially the 
same.
Comparison with Cardiovascular Disease Reviews
The only relevant review for CVD (Mills et al. 2014) con-
cerned cardiovascular events associated with smoking ces-
sation pharmacotherapies and was based on RCTs of NRT, 
bupropion and varenicline. The authors concluded “there 
was an elevated risk associated with nicotine replacement 
therapy that was driven predominantly by less serious 
events (RR 2.29; 95 % CI 1.39–3.82). When we exam-
ined major adverse cardiovascular events, we found … 
no clear evidence of harm with … nicotine replacement 
therapy (RR 1.95; 95 % CI 0.26–4.30)” (though the rel-
evant table in the review gives CI of 0.92–4.30. These esti-
mates derived from a “network meta-analysis”, incorporat-
ing also results from studies comparing results from other 
comparisons, such as bupropion (or varenicline) versus 
placebo, or versus NRT. A more conventional meta-anal-
ysis based simply on the 21 RCTs of NRT versus placebo 
gives a lower estimate, 1.38 (0.58–3.26), with a similar 
value, 1.48 (0.42–5.19), based on the three RCTs in high-
risk patients.
Relevance to nicotine‑based tobacco products
We suggest that the conclusions from this systematic 
review on the potential SAHEs of pharmaceutical NRT 
use may help to predict health effects of nicotine exposure 
from nicotine-based tobacco products. Like NRT prod-
ucts, nicotine-based tobacco products contain nicotine as 
an active ingredient, do not contain tobacco and deliver 
nicotine via several different routes (oral and inhalation 
at present). Unlike NRT products, nicotine-based tobacco 
products are regulated as tobacco products and not licensed 
as drugs or medicines. Examples include products such as 
ENDS (e-cigarettes). Though ENDS products are relatively 
new, about 4 % of adults in the USA (US) and in the UK 
currently use e-cigarettes every day or some days (Pearson 
et al. 2012; Royal College of Physicians 2016; Schoenborn 
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and Gindi 2015). Unfortunately, we know little about the 
potential SAHEs with use of these new products.
Even though these nicotine-based products are report-
edly used for different purposes (smoking cessation or rec-
reation), there appear to be many similarities in the nicotine 
delivery between NRT products and nicotine-based tobacco 
products. First, the source of added nicotine in all of these 
products is the same, pharmaceutical grade, derived from 
tobacco (Flora et al. 2015). Secondly, the route of expo-
sure and the average maximum plasma nicotine concentra-
tion (Cmax) in the blood of NRT users (4 mg nicotine gum 
or inhaler) and ENDS users are similar, typically ranging 
from 5 to 40 ng nicotine/ml plasma (D’Ruiz et al. 2015; 
Haussmann and Fariss 2016; Schneider et al. 2001; St. 
Helen et al. 2015; Vansickel and Eissenberg 2013). Thus, 
as potential serious adverse health effects of nicotine per 
se are presumably dependent on the inherent toxicity of the 
active ingredient, nicotine per se and the level of exposure, 
these two parameters appear to be very similar in both NRT 
and nicotine-based products. Unfortunately for commer-
cially available ENDS products, the enormous diversity in 
product design and aerosol delivery makes generalization 
about potential adverse health effects of these products 
challenging. Recent regulatory guidance in the US, UK and 
Europe, however, should standardize this category, result-
ing in well-characterized commercial ENDS products in 
the near future (Royal College of Physicians 2016; US 
Food and Drug Administration 2016).
Our review does not consider evidence on the potential 
adverse health effects related to long-term use of smokeless 
tobacco (SLT) including snus as a surrogate for NRT use. 
Firstly, these products differ in that a SLT user is not only 
exposed to nicotine extracted from this tobacco product, 
but also exposed to extracted compounds that may stimu-
late or mask a potential toxic effect of nicotine (Gong et al. 
2014; Hecht et al. 1986; Hoffman et al. 1987; Prokopczyk 
et al. 1987). Secondly, extensive evidence on the poten-
tial adverse health effects of snus use has been thoroughly 
reviewed in various publications. For example, epidemio-
logical evidence (Lee 2011, 2013) clearly demonstrates that 
snus use is not associated with an increased risk of cancer, 
heart disease or stroke, and provides scant support for any 
major adverse health effect. These findings are consistent 
with nicotine having very little effect on risk of SAHEs.
Comparison with authoritative body conclusions
Overall conclusions
The only SAHE from NRT exposure we identified is an 
increased incidence of respiratory congenital abnormalities 
reported in one study. For many of the SAHEs considered, 
inadequate scientific evidence was available to determine 
reliably whether NRT has an effect. Thus, except for the 
observed developmental effect, we consider the scientific 
evidence, to date, does not support an association between 
NRT exposure and SAHEs (Table 20).
The conclusions of our review agree with statements 
published by several authoritative bodies including Royal 
College of Physicians, NICE, FDA, and the US Surgeon 
General (National Institute for Health and Care Excellence 
2013; Royal College of Physicians 2016; US Food and 
Drug Administration 2013; US Surgeon General 2014). For 
example, FDA (US Food and Drug Administration 2013) 
stated that they “examined the use of NRT products over 
periods larger than 12 weeks” and “and have not identified 
any safety risks associated with such use”. In addition, a 
NICE report (Jones et al. 2012) concluded that “no authors 
have attributed serious adverse events to NRT when used as 
part of smoking harm reduction”.
Cancer
We consider the strength of scientific evidence inadequate 
to associate NRT exposure with cancer (Table 20). Only 
one well-conducted study was identified, which found no 
evidence for an effect of NRT exposure on lung cancer, 
GI cancer or overall cancer (Murray et al. 2009). While a 
study clearly demonstrating a lack of adverse effect (can-
cer) associated with NRT exposure would normally lead 
to a conclusion of “limited evidence for a lack of serious 
adverse effect”, our assessment of inadequate evidence 
took into account the study’s limited follow-up time and 
the difficulty of reliably separating effects of NRT from 
those associated with a reduction in smoking.
Similar conclusions were reached from recent reports 
from the US Surgeon General (2014) which stated that 
“there are insufficient data to conclude that nicotine 
causes or contributes to cancer in humans” and from the 
National Institute for Health and Care Excellence (2013) 
which stated that “the results of this multicentre rand-
omized controlled trial (Murray et al. 2009) suggest that 
long-term use of NRT is not associated with an increased 
incidence of harm, including cardiovascular events or 
cancer, with the latest analysis of outcome at 12.5 years 
from study outset”.
Reproductive/developmental effects
Based on one epidemiology study that demonstrated an 
increased incidence in respiratory congenital abnormali-
ties, we consider there is limited evidence of a serious 
reproductive/developmental effect (lung development) 
with NRT exposure (Table 20). It is interesting to note that 
numerous animal studies have demonstrated an association 
between prenatal nicotine exposure and lung development 
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abnormalities and offspring respiratory disease (Rehan 
et al. 2012; Spindel and McEvoy 2016).
In addition to congenital abnormalities (birth defects), 
nine additional endpoints were examined in numerous epi-
demiology and clinical studies. These showed no evidence 
of a significantly poorer outcome in NRT users. For some 
commonly studied conditions (fetal loss and spontaneous 
abortion, birthweight, gestational age, preterm birth, neona-
tal intensive care admissions and overall incidence of birth 
defects), the strength of evidence indicates limited evidence 
of a lack of effect from NRT exposure (Table 20). In fact, 
some evidence suggests infants born to pregnant smokers 
allocated to NRT use have increased birthweight and ges-
tational age at birth, and better development of their off-
spring at 2 years. For the other endpoints considered (head 
circumference/length of infant, neonatal death and Apgar 
score), an assessment of inadequate evidence was reached.
FDA classifies NRT therapies as Category “C” or “D” 
developmental hazards depending on the type of NRT 
product. For example, nicotine gum is given a Pregnancy 
Category “C” classification, indicating that animal studies 
demonstrating an adverse effect may or may not have been 
conducted as well as the absence of adequate and well-
controlled studies in pregnant women. In contrast, nicotine 
patches and inhalers are classified as a Pregnancy Category 
“D”, indicating that there are adequate well-controlled stud-
ies in pregnant women demonstrating a risk to the fetus 
(Dempsey and Benowitz 2001; Meadows 2001). These FDA 
warnings suggest a potential difference in risk between dif-
ferent types of NRT products. Our critical examination of 
the literature does not support such a difference. In fact, 
most published studies do not report the type of NRT prod-
uct used. In the few studies clearly distinguishing types 
of NRT product, no difference was seen for reproductive/
developmental end points such as birthweight and stillbirths, 
according to whether nicotine gum, patch or inhaler was 
used (Lassen et al. 2010; Strandberg-Larsen et al. 2008).
A recent report (US Surgeon General 2014) states “the 
evidence is sufficient to infer that nicotine adversely affects 
maternal and fetal health during pregnancy, contributing to 
multiple adverse outcomes such as preterm delivery and still 
birth”. However, this conclusion was inferred from studies 
of smokeless tobacco users, not from use of NRT products 
or nicotine per se delivery systems. Unlike NRT, the use of 
smokeless tobacco products results in exposure to tobacco 
extracts that contain, in addition to nicotine, numerous 
potential cytotoxic and cytoprotective compounds (Hoffman 
et al. 1987). Such a complex mixture complicates the inter-
pretation of the study results with regard to the role nicotine 
per se in the observed adverse effects.
Table 20  Strength of evidence for seriousa adverse health effects of NRT
a  Serious adverse health effects: adverse events that lead to hospitalization, significant disability or birth defects are life-threatening or result in 
death or require medical intervention to prevent one of the above outcomes (Little and Ebbert 2015; US Food and Drug Administration 2015b)
b Limited evidence suggesting an effect: A positive association was observed between exposure to NRT and this SAHE, but chance, bias and 
confounding factors could not all be ruled out with reasonable confidence. Conclusive studies are lacking. Inadequate evidence: The available 
studies are of insufficient quality, consistency or statistical power to permit a conclusion regarding a positive association between exposure to 
NRT and this SAHE. This category includes no data or conflicting evidence in multiple studies. Limited evidence suggesting a lack of effect: A 
statistically significant association was not observed between exposure to NRT and this SAHE, but a true relationship could not be ruled out with 
reasonable confidence because of a lack of statistical power, bias and/or confounding
Potential health effects Summary of evidence Assessmentb
Cancer One epidemiology study found no association 
of NRT with lung, GI or overall cancer
Inadequate evidence
Respiratory congenital abnormalities One epidemiology study found an increased 
incidence with NRT exposure
Limited evidence suggesting an effect
Fetal loss, spontaneous abortion, birthweight, 
gestational age, preterm birth, neonatal inten-
sive care admissions and overall birth defects
Evidence from multiple epidemiology and clini-
cal studies is consistent with a lack of effect 
of NRT
Limited evidence suggesting a lack of effect
Other reproductive/developmental: head circum-
ference/length of infant, neonatal death and 
Apgar score
Evidence from a small number of studies is 
consistent with a lack of effect of NRT
Inadequate evidence
Circulatory disease: AMI incidence, CVD mor-
tality, CVD admissions/re-admissions
Evidence from multiple epidemiology and clini-
cal studies is consistent with a lack of effect 
of NRT
Limited evidence suggesting a lack of effect
Stroke Evidence from a small number of studies is 
consistent with a lack of effect of NRT
Inadequate evidence
Other serious adverse health effects Evidence from a small number of studies is 
consistent with a lack of effect of NRT
Inadequate evidence
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Cardiovascular disease
We consider there is limited evidence for a lack of seri-
ous cardiovascular effects associated with NRT use 
(Table 20). The cardiovascular effects examined in numer-
ous epidemiological and clinical studies include the effect 
of NRT exposure on AMI, deaths caused by CVD and 
hospital admissions or readmissions for various cardiac-
related issues. In general, no significant overall effect was 
observed, though many studies had limitations such as few 
relevant events, short follow-up and failure to control for 
changes in smoking behaviour subsequent to NRT use. The 
type of NRT product used did not appear to have a signifi-
cant influence on serious adverse cardiovascular effects 
observed (Hubbard et al. 2005).
As evidence for a lack of increased incidence of or effect 
on cardiovascular disease, NICE (National Institute for 
Health and Care Excellence 2013) cite six studies evalu-
ating the safety of NRT products in patients with cardiac 
disease and five randomized trials evaluating biomarkers of 
potential cardiac disease in the plasma of patients treated 
with NRT for smoking cessation.
Other serious adverse health effects
NRT product warning label statements (health-related) pro-
vide authoritative bodies the opportunity to communicate 
their concern about the potential harmful effects of these 
products. For NRT products, the labels warn about potential 
risks to the child (reproductive/developmental), the heart 
(cardiac disease), the vascular system (high blood pres-
sure), the digestive system (stomach ulcers) and diabetes.
Based on these warnings and the findings from non-clin-
ical studies, we expanded our literature search to include 
terms associated not only with CVD, reproductive and 
developmental effects and cancer but also with diabetes, 
stroke, GI tract, stomach, pancreas, pancreatic and kidney 
disease. These other SAHEs following NRT exposure were 
investigated in patients and healthy population studies. Our 
strength of evidence assessment concluded there was inad-
equate evidence to associate NRT exposure with stroke or 
these other SAHEs (Table 20).
Conclusions
We critically evaluated 34 epidemiological studies and clini-
cal trials relating NRT exposure to cancer, reproductive/
developmental effects, CVD, stroke and/or other SAHEs 
in patients and in healthy populations. The overall evidence 
suffers from many limitations, the most significant being 
short-term exposure (≤12 weeks) and follow-up to NRT 
product use in most of the studies and the common failure 
to account for changes in smoking behaviour following 
NRT use. The only SAHE from NRT exposure we identified 
was an increased incidence of respiratory congenital abnor-
malities reported in one study. Other findings include lim-
ited evidence for a lack of any SAHE of NRT use on CVD 
and a range of reproduction/developmental endpoints. For 
cancer, stroke and other SAHEs, the evidence was judged 
inadequate. Though data are limited, there is no evidence 
that observed associations (or lack of associations) vary by 
type of NRT product (gum, patch, inhaler) used. Our overall 
conclusions from this systematic review agree with recent 
statements from authoritative bodies including FDA, the US 
Surgeon General, Royal College of Physicians and NICE.
Acknowledgments The work was funded by Altria Client Services 
LLC, whom we thank. We also thank Pauline Wassell, Diana Morris 
and Yvonne Cooper for assistance in typing the various drafts of the 
paper and obtaining the relevant literature.
Compliance with ethical standards 
Conflict of interest PNL, founder of P.N. Lee Statistics and Comput-
ing Ltd., is an independent consultant in statistics and an advisor in 
the fields of epidemiology and toxicology to various tobacco, pharma-
ceutical and chemical companies. This includes Altria Client Services 
LLC, the sponsors of this study, of which MWF is an employee. The 
opinions and conclusions of the authors are their own and do not neces-
sarily reflect the position of Altria Client Services LLC or its affiliates.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
Adams EK, Markowitz S, Dietz PM, Tong VT (2013) Expansion of 
Medicaid covered smoking cessation services: maternal smok-
ing and birth outcomes. Medicare Medicaid Res Rev 3(3):E1–
E23. doi:10.5600/mmrr.003.03.a02
Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Con-
nett JE (2005) The effects of smoking cessation intervention on 
a 14.5-year mortality. A randomized clinical trial. Ann Intern 
Med 142:233–239
Arany I, Grifoni S, Clark JS, Csongradi E, Maric C, Juncos LA 
(2011) Chronic nicotine exposure exacerbates acute renal 
ischemic injury. Am J Physiol Renal Physiol 301(1):F125–
F133. doi:10.1152/ajprenal.00041.2011
Aubin H-J et al (2008) Varenicline versus transdermal nicotine patch 
for smoking cessation: results from a randomised open-label 
trial. Thorax 63:717–724. doi:10.1136/thx.2007.090647
Axelsson T, Jansson PA, Smith U, Eliasson B (2001) Nicotine infusion 
acutely impairs insulin sensitivity in type 2 diabetic patients but 
not in healthy subjects. J Intern Med 249(6):539–544
Benowitz NL (2011) Smokeless tobacco as a nicotine delivery device: 
harm or harm reduction? Clin Pharmacol Ther 90(4):491–493
1591Arch Toxicol (2017) 91:1565–1594 
1 3
Benowitz NL, Gourlay SG (1997) Cardiovascular toxicity of nicotine: 
implications for nicotine replacement therapy. J Am Coll Car-
diol 29:1422–1431
Berlin I, Grange G, Jacob N, Tanguy M-L (2014) Nicotine patches in 
pregnant smokers: randomised, placebo controlled, multicentre 
trial of efficacy. BMJ 348:g1622. doi:10.1136/bmj.g1622
Black MM, Nair P, Spanier AJ (2014) Dose and timing of pre-
natal tobacco exposure: threats to early child develop-
ment. Lancet Respir Med 2(9):677–679. doi:10.1016/
S2213-2600(14)70182-1
Bradford ST, Stamatovic SM, Dondeti RS, Keep RF, Andjelkovic AV 
(2011) Nicotine aggravates the brain postischemic inflamma-
tory response. Am J Physiol Heart Circ Physiol 300(4):H1518–
H1529. doi:10.1152/ajpheart.00928.2010
Bruin JE, Gerstein HC, Holloway AC (2010) Long-term conse-
quences of fetal and neonatal nicotine exposure: a critical 
review. Toxicol Sci 116(2):364–374
Bui LM, Keen CL, Dubick MA (1995) Comparative effects of 
6-week nicotine treatment on blood pressure and components 
of the antioxidant system in male spontaneously hypertensive 
(SHR) and normotensive Wistar Kyoto (WKY) rats. Toxicology 
98(1–3):57–63
Carandang RA, Barton B, Rordorf GA, Ogilvy CS, Sims JR (2011) 
Nicotine replacement therapy after subarachnoid hemorrhage is 
not associated with increased vasospasm. Stroke 42(11):3080–
3086. doi:10.1161/STROKEAHA.111.620955
Cardinale A, Nastrucci C, Cesario A, Russo P (2012) Nicotine: spe-
cific role in angiogenesis, proliferation and apoptosis. Crit Rev 
Toxicol 42(1):68–89. doi:10.3109/10408444.2011.623150
Chowdhury P, Doi R, Tangoku A, Rayford PL (1995) Structural and 
functional changes of rat exocrine pancreas exposed to nicotine. 
Int J Pancreatol 18(3):257-264 doi:10.1007/bf02784950
Coleman T, Chamberlain C, Cooper S, Leonardi-Bee J (2011) Efficacy 
and safety of nicotine replacement therapy for smoking cessa-
tion in pregnancy: systematic review and meta-analysis. Addic-
tion 106(1):52–61. doi:10.1111/j.1360-0443.2010.03179.x
Coleman T, Chamberlain C, Davey MA, Cooper SE, Leonardi-Bee 
J (2012a) Pharmacological interventions for promoting smok-
ing cessation during pregnancy. Cochrane Database Syst Rev 
9:CD010078 doi:10.1002/14651858.CD010078
Coleman T, Cooper S, Thornton JG, Grainge MJ, Watts K, Britton J, 
Lewis S (2012b) A randomized trial of nicotine-replacement 
therapy patches in pregnancy. N Engl J Med 366(9):808–818. 
doi:10.1056/NEJMoa1109582
Cooper S et al (2014a) The SNAP trial: a randomised placebo-con-
trolled trial of nicotine replacement therapy in pregnancy–clini-
cal effectiveness and safety until 2 years after delivery, with 
economic evaluation. Health Technol Assess 18(54):1–128. 
doi:10.3310/hta18540
Cooper S, Taggar J, Lewis S, Marlow N, Dickinson A, Whitemore 
R, Coleman T (2014b) Effect of nicotine patches in preg-
nancy on infant and maternal outcomes at 2 years: follow-
up from the randomised, double-blind, placebo-controlled 
SNAP trial. Lancet Respir Med 2(9):728–737. doi:10.1016/
S2213-2600(14)70157-2
Cordier JF (2014) Tobacco weaning in the pregnant woman: failure of 
nicotine patches. Rev Prat 64(6):769
Dempsey DA, Benowitz NL (2001) Risks and benefits of nicotine to 
aid smoking cessation in pregnancy. Drug Saf 24(4):277–322
Dhalwani NN, Szatkowski L, Coleman T, Fiaschi L, Tata LJ (2015) 
Nicotine replacement therapy in pregnancy and major con-
genital anomalies in offspring. Pediatrics 135(5):859–867. 
doi:10.1542/peds.2014-2560
D’Ruiz CD, Graff DW, Yan XS (2015) Nicotine delivery, tolerability 
and reduction of smoking urge in smokers following short-term 
use of one brand of electronic cigarettes. BMC Public Health 
15:991. doi:10.1186/s12889-015-2349-2
Ebbert JO, Montori V, Vickers KS, Erwin PC, Dale LC, Stead LF 
(2007) Interventions for smokeless tobacco use cessation. 
Cochrane Database Syst Rev (4):CD004306
Eliasson B, Taskinen M-R, Smith U (1996) Long-term use of nicotine 
gum is associated with hyperinsulinemia and insulin resistance. 
Circulation 94:878–881
El-Mohandes AAE, Windsor R, Tan S, Perry DC, Gantz MG, Kiely 
M (2013) A randomized clinical trial of trans-dermal nicotine 
replacement in pregnant African-American smokers. Matern 
Child Health J 17(5):897–906
Elzi L et al (2006) A smoking cessation programme in HIV-infected 
individuals: a pilot study. Antivir Ther 11(6):787–795
Epifano L et al (1992) Effect of cigarette smoking and of a transder-
mal nicotine delivery system on glucoregulation in type 2 dia-
betes mellitus. Eur J Clin Pharmacol 43(3):257–263
Fahim MA, Nemmar A, Al-Salam S, Dhanasekaran S, Shafiullah M, 
Yasin J, Hassan MY (2014) Thromboembolic injury and sys-
temic toxicity induced by nicotine in mice. Gen Physiol Bio-
phys 33(3):345–355. doi:10.4149/gpb_2014012
Ferguson SG, Shiffman S, Gitchell JG (2011) Nicotine replacement 
therapies: patient safety and persistence. Patient Relat Outcome 
Meas 2:111–117. doi:10.2147/prom.s11545
Flora JW et al (2015) Characterization of potential impurities and 
degradation products in electronic cigarette formulations and 
aerosols. Regul Toxicol Pharmacol 74:1–11. doi:10.1016/j.
yrtph.2015.11.009
Ford CL, Zlabek JA (2005) Nicotine replacement therapy and cardio-
vascular disease. Mayo Clin Proc 80(5):652–656
Forest S (2010) Controversy and evidence about nicotine replacement 
therapy in pregnancy. MCN Am J Matern Child Nurs 35(2):89–
95. doi:10.1097/NMC.0b013e3181cafba4
Forinash AB, Pitlick JM, Clark K, Alstat V (2010) Nicotine replace-
ment therapy effect on pregnancy outcomes. Ann Pharmacother 
44(11):1817–1821. doi:10.1345/aph.1P279
Fucito LM et al (2014) Addressing the evidence for FDA nicotine 
replacement therapy label changes: a policy statement of the 
Association for the Treatment of Tobacco use and Dependence 
and the Society for Research on Nicotine and Tobacco. Nicotine 
Tob Res 16(7):909–914. doi:10.1093/ntr/ntu087
Gaither KH, Brunner Huber LR, Thompson ME, Huet-Hudson YM 
(2009) Does the use of nicotine replacement therapy during 
pregnancy affect pregnancy outcomes? Matern Child Health J 
13(4):497–504. doi:10.1007/s10995-008-0361-1
Gong WY et al (2014) Flavonoid components in Scutellaria bai-
calensis inhibit nicotine-induced proliferation, metastasis 
and lung cancer-associated inflammation in vitro. Int J Oncol 
44(5):1561–1570. doi:10.3892/ijo.2014.2320
Grando SA (2014) Connections of nicotine to cancer. Nat Rev Cancer 
14(6):419–429. doi:10.1038/nrc3725
Greenland S, Satterfield MH, Lanes SF (1998) A meta-analysis to 
assess the incidence of adverse effects associated with the trans-
dermal nicotine patch. Drug Saf 18(4):297–308
Hall BJ, Cauley M, Burke DA, Kiany A, Slotkin TA, Levin ED (2016) 
Cognitive and behavioral impairments evoked by low-level 
exposure to tobacco smoke components: comparison with nico-
tine alone. Toxicol Sci 151(2):236–244. doi:10.1093/toxsci/
kfw042
Harrell PT, Simmons VN, Correa JB, Padhya TA, Brandon TH (2014) 
Electronic nicotine delivery systems (“e-cigarettes”): review of 
safety and smoking cessation efficacy. Otolaryngol Head Neck 
Surg 151(3):381–393. doi:10.1177/0194599814536847
Haussmann H-J, Fariss MW (2016) Comprehensive review of epi-
demiological and animal studies on the potential carcinogenic 
1592 Arch Toxicol (2017) 91:1565–1594
1 3
effects of nicotine per se. Crit Rev Toxicol. doi:10.1080/10408
444.2016.1182116
Haustein K-O, Krause J, Haustein H, Rasmussen T, Cort N (2002) 
Effects of cigarette smoking or nicotine replacement on cardio-
vascular risk factors and parameters of haemorheology. J Intern 
Med 252(2):130–139
Hecht SS, Rivenson A, Braley J, DiBello J, Adams JD, Hoffmann D 
(1986) Induction of oral cavity tumors in F344 rats by tobacco-
specific nitrosamines and snuff. Cancer Res 46(8):4162–4166
Higgins JPT et al (2011) The Cochrane Collaboration’s tool for 
assessing risk of bias in randomised trials. BMJ 343:889–893
Hoffman D, Adams JD, Lisk D, Fisenne I, Brunnemann KD (1987) 
Toxic and carcinogenic agents in dry and moist snuff. J Natl 
Cancer Inst 79(6):1281–1286
Hotham ED, Gilbert AL, Atkinson ER (2006) A randomised-con-
trolled pilot study using nicotine patches with pregnant women. 
Addict Behav 31:641–648
Hubbard R, Lewis S, Smith C, Godfrey C, Smeeth L, Farrington P, 
Britton J (2005) Use of nicotine replacement therapy and the 
risk of acute myocardial infarction, stroke, and death. Tob Con-
trol 14:416–421
Hughes JR (2000) New treatments for smoking cessation. CA Cancer 
J Clin 50(3):143–151
Improgo MR, Tapper AR, Gardner PD (2011) Nicotinic acetylcholine 
receptor-mediated mechanisms in lung cancer. Biochem Phar-
macol 82(8):1015–1021. doi:10.1016/j.bcp.2011.05.020
International Agency for Research on Cancer (2007) Smokeless 
tobacco and some tobacco-specific N-nitrosamines vol 89. 
IARC Monographs on the evaluation of carcinogenic risks 
to humans. World Health Organization, IARC, Lyon, France. 
http://monographs.iarc.fr/ENG/Monographs/vol89/mono89.pdf
Jacobson FL, Jaklitsch MT (2013) Tobacco cessation and health pro-
motion. J Surg Oncol 108(5):312–314. doi:10.1002/jso.23395
Jones S, Cleves A, Morgan F, Withers K, White J, Dale M (2012) 
NICE public health guidance on tobacco harm reduction Safety, 
risk and pharmacokinetics profiles of tobacco harm reduction 
technologies. Cardiff and Vale University Health Board, Cardiff
Joseph AM, Fu SS (2003) Safety issues in pharmacotherapy for 
smoking in patients with cardiovascular disease. Prog Cardio-
vasc Dis 45(6):429–441
Joseph AM et al (1996) The safety of transdermal nicotine as an aid 
to smoking cessation in patients with cardiac disease. N Engl J 
Med 335:1792–1798
Kapur B, Hackman R, Selby P, Klein J, Koren G (2001) Randomized, 
double-blind, placebo-controlled trial of nicotine replacement 
therapy in pregnancy. Curr Ther Res Clin Exp 62:274–278. 
doi:10.1016/S0011-393X(01)80011-4
Kimmel SE, Berlin JA, Miles C, Jaskowiak J, Carson JL, Strom BL 
(2001) Risk of acute first myocardial infarction and use of 
nicotine patches in a general population. J Am Coll Cardiol 
37:1297–1302
Klaunig JE (2013) Chemical carcinogenesis. In: Klaassen CD (ed) 
Casarett and Doull’s toxicology: the basis science of poison. 
McGraw-Hill, New York
Klevans LR, Gebber GL (1970) Comparison of differential secretion 
of adrenal catecholamines by splanchnic nerve stimulation and 
cholinergic agents. J Pharmacol Exp Ther 172(1):69–76
Kostygina G, England L, Ling P (2016) New product marketing blurs 
the line between nicotine replacement therapy and smokeless 
tobacco Pproducts. Am J Public Health 106(7):1219–1222. 
doi:10.2105/ajph.2016.303057
Kotz D, Brown J, West R (2015) In reply–Electronic cigarettes are 
efficacious. Mayo Clin Proc 90(3):417–418. doi:10.1016/j.
mayocp.2014.12.018
Lam DC et al (2016) Nicotinic acetylcholine receptor expression 
in human airway correlates with lung function. Am J Physiol 
Lung Cell Mol Physiol 310(3):L232–L239. doi:10.1152/
ajplung.00101.2015
Lancaster T (2014) In pregnant smokers, the nicotine patch did 
not increase abstinence or birthweight more than pla-
cebo. [Commentary] Ann Intern Med 160(12):JC11 
doi:10.7326/0003-4819-160-12-201406170-02011
Lassen TH, Madsen M, Skovgaard LT, Strandberg-Larsen K, 
Olsen J, Andersen AM (2010) Maternal use of nico-
tine replacement therapy during pregnancy and off-
spring birthweight: a study within the Danish National 
Birth Cohort. Paediatr Perinat Epidemiol 24(3):272–281. 
doi:10.1111/j.1365-3016.2010.01104.x
Lau PP, Li L, Merched AJ, Zhang AL, Ko KW, Chan L (2006) Nico-
tine induces proinflammatory responses in macrophages and the 
aorta leading to acceleration of atherosclerosis in low-density 
lipoprotein receptor(−/−) mice. Arterioscler Thromb Vasc Biol 
26(1):143–149. doi:10.1161/01.atv.0000193510.19000.10
Lavelle C, Birek C, Scott DA (2003) Are nicotine replacement strat-
egies to facilitate smoking cessation safe? J Can Dent Assoc 
69(9):592–597
Lee PN (2011) Summary of the epidemiological evidence relating 
snus to health. Regul Toxicol Pharmacol 59:197–214
Lee PN (2013) Epidemiological evidence relating snus to health—an 
updated review based on recent publications. Harm Reduct J 
10(1):36. doi:10.1186/1477-7517-10-36
Lee SM, Landry J, Jones PM, Burhrmann O, Morley-Forster P (2013) 
The effectiveness of a perioperative smoking cessation pro-
gram: a randomized clinical trial. Anesth Analg 117(3):605–
613. doi:10.1213/ANE.0b013e318298a6b0
Little MA, Ebbert JO (2015) The safety of treatments for tobacco use 
disorder. Expert Opin Drug Saf:1-9 doi:10.1517/14740338.201
6.1131817
Marks MJ, Stitzel JA, Collins AC (1987) Influence of kinetics of nico-
tine administration on tolerance development and receptor lev-
els. Pharmacol Biochem Behav 27(3):505–512
Marsh HS, Dresler CM, Choi JH, Targett DA, Gamble ML, Strahs 
KR (2005) Safety profile of a nicotine lozenge compared with 
that of nicotine gum in adult smokers with underlying medical 
conditions: a 12-week, randomized, open-label study. Clin Ther 
27:1571–1587
McNeill A, Foulds J, Bates C (2001) Regulation of nicotine replace-
ment therapies (NRT): a critique of current practice. Addiction 
96(12):1757–1768. doi:10.1080/09652140120089508
Meadows M (2001) Pregnancy and the drug dilemma. FDA Consum 
35(3):16–20
Meine TJ, Patel MR, Washam JB, Pappas PA, Jollis JG (2005) Safety 
and effectiveness of transdermal nicotine patch in smok-
ers admitted with acute coronary syndromes. Am J Cardiol 
95(8):976–978
Milidou I, Henriksen TB, Jensen MS, Olsen J, Søndergaard C 
(2012) Nicotine replacement therapy during pregnancy and 
infantile colic in the offspring. Pediatrics 129(3):e652–e658. 
doi:10.1542/peds.2011-2281
Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO (2010) Adverse 
events associated with nicotine replacement therapy (NRT) for 
smoking cessation. A systematic review and meta-analysis of 
one hundred and twenty studies involving 177,390 individuals. 
Tob Induc Dis 8:8 doi:10.1186/1617-9625-8-8
Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ (2014) Cardio-
vascular events associated with smoking cessation pharmaco-
therapies: a network meta-analysis. Circulation 129(1):28–41. 
doi:10.1161/CIRCULATIONAHA.113.003961
Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, 
Hilleman DE (2007) Intensive smoking cessation intervention 
reduces mortality in high-risk smokers with cardiovascular dis-
ease. Chest 131(2):446–452
1593Arch Toxicol (2017) 91:1565–1594 
1 3
Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P 
(2009) Effectiveness and safety of nicotine replacement therapy 
assisted reduction to stop smoking: systematic review and meta-
analysis. BMJ 338:867–871
Morales-Suarez-Varela MM, Bille C, Christensen K, Olsen J (2006) 
Smoking habits, nicotine use, and congenital malformations. 
Obstet Gynecol 107(1):51–57
Murray RP, Connett JE, Zapawa LM (2009) Does nicotine replace-
ment therapy cause cancer? Evidence from the Lung Health 
Study. Nicotine Tob Res 11(9):1076–1082. doi:10.1093/ntr/
ntp104
Myung SK, Yoo KY, Oh SW, Park SH, Seo HG, Hwang SS, Park SK 
(2007) Meta-analysis of studies investigating one-year effec-
tiveness of transdermal nicotine patches for smoking cessation. 
Am J Health Syst Pharm 64(23):2471–2476
National Heart Lung and Blood Institute (2014a) Quality assess-
ment of case-control studies—Last updated March 2014. 
Bethesda: National Heart, Lung and Blood Institute, National 




National Heart Lung and Blood Institute (2014b) Quality assessment 
tool for observational cohort and cross-sectional studies—Last 
updated March 2014. Bethesda: National Heart, Lung and 
Blood Institute, National Institutes of Health, US Department of 
Health and Human Services. http://www.nhlbi.nih.gov/health-
pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/
cohort.htm. Accessed Oct
National Institute for Health and Care Excellence (2013) Smoking 
harm reduction: gaps in the evidence. http://publications.nice.
org.uk/tobacco-harm-reduction-approaches-to-smoking-ph45/
gaps-in-the-evidence
Nicholson JA, Smith D, Scott MH (2010) Nicotine gum causing 
pancreatitis: a case report. Pancreas 39(1):116. doi:10.1097/
MPA.0b013e3181b65577
Oncken CA, Kranzler HR (2009) What do we know about the role of 
pharmacotherapy for smoking cessation before or during preg-
nancy? Nicotine Tob Res 11(11):1265–1273. doi:10.1093/ntr/
ntp136
Oncken CA, Hatsukami DK, Lupo VR, Lando HA, Gibeau LM, 
Hansen RJ (1996) Effects of short-term use of nicotine gum in 
pregnant smokers. Clin Pharmacol Ther 59:654–661
Oncken CA, Hardardottir H, Hatsukami DK, Lupo VR, Rodis JF, 
Smeltzer JS (1997) Effects of transdermal nicotine or smoking 
on nicotine concentrations and maternal-fetal hemodynamics. 
Obstet Gynecol 90(4):569–574
Oncken C, Dornelas E, Greene J, Sankey H, Glasmann A, Feinn R, 
Kranzler HR (2008) Nicotine gum for pregnant smokers: a 
randomized controlled trial. Obstet Gynecol 112(4):859–867. 
doi:10.1097/AOG.0b013e318187e1ec
Osadchy A, Kazmin A, Koren G (2009) Nicotine replacement therapy 
during pregnancy: recommended or not recommended? J Obstet 
Gynaecol Can 31(8):744–747
Paciullo CA, Short MR, Steinke DT, Jennings HR (2009) Impact of 
nicotine replacement therapy on postoperative mortality fol-
lowing coronary artery bypass graft surgery. Ann Pharmacother 
43(7):1197–1202. doi:10.1345/aph.1L423
Panos NG, Tesoro EP, Kim KS, Mucksavage JJ (2010) Outcomes 
associated with transdermal nicotine replacement therapy in 
a neurosurgery intensive care unit. Am J Health Syst Pharm 
67(16):1357–1361. doi:10.2146/ajhp090402
Paulson JR et al (2010) Nicotine exacerbates brain edema during 
in vitro and in vivo focal ischemic conditions. J Pharmacol Exp 
Ther 332(2):371–379. doi:10.1124/jpet.109.157776
Pauly JR, Slotkin TA (2008) Maternal tobacco smoking, nicotine 
replacement and neurobehavioural development. Acta Paediatr 
97(10):1331–1337. doi:10.1111/j.1651-2227.2008.00852.x
Pearson JL, Richardson A, Niaura RS, Vallone DM, Abrams DB 
(2012) e-Cigarette awareness, use, and harm perceptions in US 
adults. Am J Public Health 102(9):1758–1766. doi:10.2105/
AJPH.2011.300526
Pollak KI et al (2007) Nicotine replacement and behavioral ther-
apy for smoking cessation in pregnancy. Am J Prev Med 
33(4):297–305
Prokopczyk G, Adams JD, LaVoie EJ, Hoffmann D (1987) 
Effect of snuff and nicotine on DNA methylation by 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogen-
esis 8(10):1395–1397
Qiu BS, Cho CH, Ogle CW (1991) Chronic nicotine treatment inten-
sifies gastric ulceration by cold-restraint stress in rats. Agents 
Actions 33(3–4):367–370
Rehan VK et al (2012) Perinatal nicotine exposure induces 
asthma in second generation offspring. BMC Med 10:129. 
doi:10.1186/1741-7015-10-129
Renda A, Nashmi R (2014) Chronic nicotine pretreatment is suf-
ficient to upregulate alpha4* nicotinic receptors and increase 
oral nicotine self-administration in mice. BMC Neurosci 15:89. 
doi:10.1186/1471-2202-15-89
Rennard S et al (1994) Nicotine replacement therapy for patients with 
coronary artery disease. Working Group for the Study of Trans-
dermal Nicotine in Patients with Coronary Artery Disease. Arch 
Intern Med 154(9):989–995
Reuther WJ, Brennan PA (2014) Is nicotine still the bad guy? Sum-
mary of the effects of smoking on patients with head and neck 
cancer in the postoperative period and the uses of nicotine 
replacement therapy in these patients. Br J Oral Maxillofac 
Surg 52(2):102–105. doi:10.1016/j.bjoms.2013.11.003
Rore C, Brace V, Danielian P, Williams D (2008) Smoking ces-
sation in pregnancy. Expert Opin Drug Saf 7(6):727–737. 
doi:10.1517/14740330802196756
Royal College of Physicians (2016) Nicotine without smoke: tobacco 
harm reduction. RCP, London. https://www.rcplondon.ac.uk/
file/3563/download?token=uV0R0Twz
Schneider NG, Olmstead RE, Franzon MA, Lunell E (2001) The nic-
otine inhaler: clinical pharmacokinetics and comparison with 
other nicotine treatments. Clin Pharmacokinet 40(9):661–684
Schoenborn CA, Gindi RM (2015) Electronic cigarette use among 
adults: United States, 2014. NCHS Data Brief 217:1–8
Schroeder DR, Ogburn PLJ, Hurt RD, Croghan IT, Ramin KD, Offord 
KP, Moyer TP (2002) Nicotine patch use in pregnant smok-
ers: smoking abstinence and delivery outcomes. J Matern Fetal 
Neonatal Med 11:100–107
Shahab L, Goniewicz M (2014) Electronic cigarettes are at least as 
effective as nicotine patches for smoking cessation. Evid Based 
Med 19(4):133. doi:10.1136/eb-2013-101690
Shields PG (2011) Long-term nicotine replacement therapy: can-
cer risk in context. Cancer Prev Res (Phila) 4(11):1719–1723. 
doi:10.1158/1940-6207.CAPR-11-0453
Shiffman S, Dresler CM, Hajek P, Gilburt SJA, Targett DA, Strahs KR 
(2002) Efficacy of a nicotine lozenge for smoking cessation. 
Arch Intern Med 162:1267–1276
Shiffman S, Fant RV, Buchhalter AR, Gitchell JG, Henningfield JE 
(2005) Nicotine delivery systems. Expert Opin Drug Deliv 
2(3):563–577
Siahpush M, Shaikh RA, McCarthy M, Sikora Kessler A, Tibbits 
M, Singh GK (2015) Association between duration of use 
of pharmacotherapy and smoking cessation: findings from 
a national survey. BMJ Open 5(1):e006229. doi:10.1136/
bmjopen-2014-006229
1594 Arch Toxicol (2017) 91:1565–1594
1 3
Slotkin TA (2008) If nicotine is a developmental neurotoxicant in ani-
mal studies, dare we recommend nicotine replacement therapy 
in pregnant women and adolescents? Neurotoxicol Teratol 
30(1):1–19
Smith PM, Reilly KR, Houston MN, DeBusk RF, Taylor CB (2002) 
Application of a nurse-managed inpatient smoking cessation 
program. Nicotine Tob Res 4(2):211–222
Spindel ER, McEvoy CT (2016) The role of nicotine in the effects 
of maternal smoking during pregnancy on lung development 
and childhood respiratory disease. Implications for dangers 
of e-cigarettes. Am J Respir Crit Care Med 193(5):486–494. 
doi:10.1164/rccm.201510-2013PP
Sridharan MR, Flowers NC, Hand RC, Hand JW, Horan LG (1985) 
Effect of various regimens of chronic and acute nicotine 
exposure on myocardial infarct size in the dog. Am J Cardiol 
55(11):1407–1411
St. Helen G, Havel C, Dempsey D, Jacob PI, Benowitz NL (2015) 
Nicotine delivery, retention, and pharmacokinetics from various 
electronic cigarettes. Addiction 111(3):535–544. doi:10.1111/
add.13183
Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce K, Cahil K, 
Lancaster T (2012) Nicotine replacement therapy for smoking 
cessation (review). The Cochrane Collaboration. Wiley, New 
York. http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD000146.pub4/abstract
Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, 
Hoover DR, Carson JL (2009) Triple-combination pharmaco-
therapy for medially ill smokers: a randomized trial. Ann Intern 
Med 150(7):447–454
Strandberg-Larsen K, Tinggaard M, Nybo Andersen AM, Olsen J, 
Grønbaek M (2008) Use of nicotine replacement therapy during 
pregnancy and stillbirth: a cohort study. BJOG 115(11):1405–
1410. doi:10.1111/j.1471-0528.2008.01867.x
Swamy GK et al (2009) Predictors of adverse events among preg-
nant smokers exposed in a nicotine replacement therapy 
trial. Am J Obstet Gynecol 201(4):354–357. doi:10.1016/j.
ajog.2009.06.006
Tappin D et al (2015) Financial incentives for smoking cessation 
in pregnancy: randomised controlled trial. BMJ 350:h134. 
doi:10.1136/bmj.h134
Theophilus EH, Hayes JR, Potts RJ, Ayres PH, Williams CD, Gar-
ner CD (2012) Toxicological evaluation of smokeless tobacco: 
90-day rodent feeding studies. Exp Toxicol Pathol 64(1–2):15–
24. doi:10.1016/j.etp.2010.05.013
Thomsen T, Tønnesen H, Okholm M, Kroman N, Maibom A, Sau-
erberg M-L, Møller AM (2010) Brief smoking cessation inter-
vention in relating to breast cancer surgery: a randomized con-
trolled trial. Nicotine Tob Res 12(11):1118–1124. doi:10.1093/
ntr/ntq158
Torp-Pedersen T, Boyd HA, Poulsen G, Haargaard B, Wohlfahrt J, 
Holmes JM, Melbye M (2010) In-utero exposure to smoking, 
alcohol, coffee, and tea and risk of strabismus. Am J Epidemiol 
171(8):868–875
Tzivoni D, Keren A, Meyler S, Khoury Z, Lerer T, Brunel P (1998) 
Cardiovascular safety of transdermal nicotine patches in 
patients with coronary artery disease who try to quit smoking. 
Cardiovasc Drugs Ther 12:239–244
US Food and Drug Administration (2013) Modifications to labeling 
of nicotine replacement therapy products for over-the-counter 
human use. Federal Register, vol 78. Department of Health and 
Human Services, USA, pp 19718–19721
US Food and Drug Administration (2015a) Drugs@FDA, Nicorette. 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.
cfm
US Food and Drug Administration (2015b) U.S. Code of Federal 
Regulations. Title 21. Food and drugs. Part 312. Investigational 
New Drug Application (21CFR312.32). USA. http://www.
accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm. 
Accessed Apr 2015, Last updated 01 Apr 2015
US Food and Drug Administration (2016) Deeming tobacco products 
to be subject to the Federal Food, Drug, and Cosmetic Act, as 
amended by the Family Smoking Prevention and Tobacco Con-
trol Act: regulations on the sale and distribution of tobacco 
products and required warning statements for tobacco products 
vol 81. Federal Register, No. 90 edn. Department of Health and 
Human Services, USA
US Surgeon General (2014) The health consequences of smok-
ing—50 years of progress: a report of the Surgeon General. 
US Department of Health and Human Services, Centers for 
Disease Control and Prevention, National Center for Chronic 
Disease Prevention and Health Promotion, Office on Smoking 
and Health, Atlanta, Georgia. http://www.surgeongeneral.gov/
library/reports/index.html
Vansickel AR, Eissenberg T (2013) Electronic cigarettes: effective 
nicotine delivery after acute administration. Nicotine Tob Res 
15(1):267–270. doi:10.1093/ntr/ntr316
Waldum HL et al (1996) Long-term effects of inhaled nicotine. Life 
Sci 58:1339–1346
Wang L, Kittaka M, Sun N, Schreiber SS, Zlokovic BV (1997) 
Chronic nicotine treatment enhances focal ischemic brain injury 
and depletes free pool of brain microvascular tissue plasmino-
gen activator in rats. J Cereb Blood Flow Metab 17(2):136–146. 
doi:10.1097/00004647-199702000-00002
Weinberger AH, Smith PH, Kaufman M, McKee SA (2014) Consid-
eration of sex in clinical trials of transdermal nicotine patch: a 
systematic review. Exp Clin Psychopharmacol 22(5):373–383. 
doi:10.1037/a0037692
Wilson RH, McNaught JB, De Eds F (1938) Chronic nicotine tox-
icity: IV. Effect of nicotine-containing diets on histology and 
weights of organs in albino rats. J Ind Hyg Toxicol 20:468-481
Wisborg K, Henriksen TB, Jespersen LB, Secher NJ (2000) Nicotine 
patches for pregnant smokers: a randomized controlled study. 
Obstet Gynecol 96:967–971
Wong D, Koo MW, Shin VY, Liu ES, Cho CH (2002) Pathogenesis of 
nicotine treatment and its withdrawal on stress-induced gastric 
ulceration in rats. Eur J Pharmacol 434(1–2):81–86
Wong MK, Barra NG, Alfaidy N, Hardy DB, Holloway AC (2015) 
Adverse effects of perinatal nicotine exposure on reproduc-
tive outcomes. Reproduction 150(6):R185–R193. doi:10.1530/
rep-15-0295
Woolf KJ, Zabad MN, Post JM, McNitt S, Williams GC, Bisognano 
JD (2012) Effect of nicotine replacement therapy on cardiovas-
cular outcomes after acute coronary syndromes. Am J Cardiol 
110(7):968–970. doi:10.1016/j.amjcard.2012.05.028
Zaton´ski W, Zaton´ski M (2015) Cytisine versus nicotine for smok-
ing cessation. N Engl J Med 372(11):1072. doi:10.1056/
NEJMc1500342
Zhou MS, Chadipiralla K, Mendez AJ, Jaimes EA, Silverstein RL, 
Webster K, Raij L (2013) Nicotine potentiates proatherogenic 
effects of oxLDL by stimulating and upregulating macrophage 
CD36 signaling. Am J Physiol Heart Circ Physiol 305(4):H563–
H574. doi:10.1152/ajpheart.00042.2013
Zhu JL, Olsen J, Liew Z, Li J, Niclasen J, Obel C (2014) Paren-
tal smoking during pregnancy and ADHD in children: the 
Danish national birth cohort. Pediatrics 134(2):e382–e388. 
doi:10.1542/peds.2014-0213
